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History of Polo-like Kinases 
 
The family of Polo-like kinases (PLKs) plays important roles in cell cycle progression, 
especially in the event of mitosis. (Glover et al., 1998; Nigg, 1998) It was first 
discovered as Polo in Drosophila melanogaster over twenty years ago where 
neuroblast cells that were homozygous for the mutated polo alleles showed abrupt 
spindle formation that resulted in polyploidy cells. (Sunkel and Glover, 1988) 
Following this, PLKs homologues in yeast, worm, frog, mouse and human are also 
discovered (Tab. I). All PLKs contain the highly conserved Ser/Thr kinase domains at 
the N-termini and polo-box(s), a string of highly conserved thirty amino acids, at the 
non-catalytic C-termini. (Lowery et al., 2005) In Saccharomyces cerevisiae, a 
loss-in-function of Cdc5 can be readily compensated by over-expressing either 
mammalian PLK1 or PLK3. (Lee and Erikson, 1997; Ouyang et al., 1997) It is 
therefore evident that PLKs’ functions are conserved throughout evolution, implying 
their importance in species survival.  
 
Structures and Domains of Polo-like Kinases 
 
As mentioned, Polo-like kinases contain two highly conserved structural features, the 
kinase domains and the polo-box domains. (Fig. I) The N-terminal Ser/Thr kinase 
domain contains a T-loop that is important for PLK activation through 
phosphorylation at specific residues, which is common to other kinases as well. 
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(Johnson et al., 1996) Mutation of a conserved residue in the T-loop, Thr210, in 
human PLK1 to Asp that mimics phosphorylated Thr210 can cause activation of 
PLK1. (Jang et al., 2002b) Similar event also has been reported in Xenopus laevis 
Plx1 at Thr201. (Qian et al., 1999) With reference to Protein Kinase A, the 
phosphorylation is believed to stabilize the T-loop in an open and extended 
conformation to facilitate substrate binding. (Knighton et al., 1991a; Knighton et al., 
1991b) In human PLK1, the substrate recognition motif has been elucidated, which 
consists of Glu/Asp at the -2 position and a hydrophobic residue in the +1 position 
relative to the phosphorylated Ser/Thr residue. (Lowery et al., 2005) 
 
Polo-box domain (PBD) is a unique signature for PLKs that harbors two tandem 
polo-box repeats except for Sak or PLK4 that only has a single polo-box. (Leung et 
al., 2002) PBD has been showed to involve in negatively regulating PLKs kinase 
activity as C-terminal deletion in wild-type and T210D PLK mutant gain noticeable 
increase in kinase activity. (Jang et al., 2002a; Mundt et al., 1997) Another interesting 
function of PBD lies in its ability to localize PLKs to certain cellular structures, most 
prominently to centrosomes and midbody/midzone at certain stages in mitosis. 
(Golsteyn et al., 1994; Lee et al., 1995) A recent breakthrough in exploring the 
molecular basis of PBD reveals the PBD as a phosphopeptide-binding motif and this 
shed lights on the mechanism regarding spatial and temporal regulations of PLKs at 
various stages of mitosis. (Elia et al., 2003a; Elia et al., 2003b) 
 
The optimal phosphopeptide motif that is recognized by PBD of PLKs is determined 
through peptide library screening and revealed as 
[Pro/Phe]-[φ/Pro]-[φ/AlaCdc5p/GlnPLK2]-[Thr/Gln/His/Met]-Ser-[pThr/pSer]-[Pro/
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X] (φ represents hydrophobic amino acids), with strong selection for Ser in the 
pThr/pSer-1 position, which is observed in all members of human PLKs, Xenopus 
Plx1, and Saccharomyces cerevisiae Cdc5p. (Elia et al., 2003b) Crytallized structure 
of human PLK1 PBD binding the optimal motif (Pro-Met-Gln-Ser-pThr-Pro-Leu) 
further identifies other key residues that are important in mediating the 
phosphopeptide binding. (Elia et al., 2003b) These include His-538 and Lys-540, 
which if mutated to Ala will abolish the binding. (Elia et al., 2003b) The side chains 
of these two residues form a pincer-like arrangement that establish direct contact with 
the phosphate group as revealed from the crystal structure. (Elia et al., 2003b) 
Another key residue that is important to the phosphopeptide binding is the critically 
conserved Trp-414, (Elia et al., 2003b) which has been showed to eliminate 
centrosomal localization of PLK1 in W414F PLK1 mutant. (Lee and Erikson, 1997) 
 
Considering the capability of phosphopeptide-binding of PBD, it is therefore rational 
to infer that PLKs are being localized and regulated through their PBD. PLKs can be 
localized to the target proteins that have been phopshorylated prior by cell cycle 
kinases such as Cell cycle-dependent kinase 1 (Cdk1) to generate docking sites for 
PLKs via their PBD. (Elia et al., 2003a; Elia et al., 2003b) Interestingly, PLK1 can be 
blocked from its binding partner, microtubule-associated protein regulating 
cytokinesis (Prc1) by Cdk1 until Cdk1 activity wanes during anaphase. (Neef et al., 
2007) These are excellent examples on both the spatial and temporal regulations of 





Functions of Polo-like Kinases 
 
Cell cycle is a tightly regulated physiological process that employs multiple 
checkpoints during G1, S, G2, and M phases to ensure the fidelity of genome 
replication and thus its integrity to prevent genome instability. (Elledge, 1996) As 
with other cell cycle kinases, PLKs expressions are tightly regulated in a cyclical 
fashion with low expressions in G1 phase and peak at G2/M phase, which coincide to 
its roles in mitosis. (Golsteyn et al., 1994) PLKs expressions throughout the cell cycle 
are mainly regulated through phosphorylation and ubiquitin-dependent proteolysis 
that involves the anaphase promoting complex/cyclosome with its activator Cdh1 
(APC/CCdh1). (Nigg, 2001; Peters, 2002) The functions of human PLK1 are currently 
the most elaborated and therefore will be the focus for this review. In addition, 
examples from other species or its other members will be highlighted when it deems 
suitable.  
 
Replication of the chromosomes during S phase is monitored strictly by the DNA 
damage checkpoint to prevent any genome defects from passing to the daughter cells. 
(Zhou and Elledge, 2000)  PLK1’s role in this phase has been identified as a possible 
target of ataxia telangiectasia mutated (ATM) or ATM-related proteins (ATR), the 
transducers of the DNA damage signaling pathway. (van Vugt et al., 2001) Activity of 
PLK1 is inhibited when the DNA damage checkpoint is activated following an insult 
to the genome. The inhibition appears to be mediated by blocking PLK1 activation 
because expression of PLK1 activation mutant (T210D/S137D) can partially override 
the DNA damage-induced G2/M arrest. (Smits et al., 2000) The actions of ATM/ATR 
on PLK1 are later demonstrated by using radio-sensitizing agent i.e., caffeine that 
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specifically inhibits ATM/ATR and reverses the PLK1 inhibition during 
radiation-induced DNA damage. (van Vugt et al., 2001)  
 
PLK1 has been showed to immunoprecipitate together with tumor suppressor p53, 
which resulted in terminating the trans-activating activity of p53. (Ando et al., 2004) 
p53 expression is greatly enhanced when DNA damage checkpoint is activated and its 
function is to arrest the cell cycle at G1 via the action of p21 in order to repair the 
damaged DNA; or to initiate apoptosis if the damage is too extensive. (Levine, 1997) 
However, expression of ATM can antagonize the inhibitory effect of PLK1 on p53. 
(Ando et al., 2004) Therefore, ATM/ATR inhibition of PLK1 seems crucial to allow 
G2/M arrest and may help in liberating p53 from the inhibitory effect of PLK1 in 
response to DNA damage. Other members of the PLKs family, PLK2 and PLK3 have 
also been implicated in DNA damage response but PLK3 seems to play a more 
prominent yet contrary role. Instead of negatively affecting the DNA damage 
checkpoint, PLK3 positively regulates p53 activity and therefore promoting cell cycle 
arrest. (Xie et al., 2005)  
 
Cell division cycle 2 (Cdc2)/Cyclin B complex orchestrates the events during M 
phase and its activation during mitotic onset requires cell division cycle 25 homolog 
C (Cdc25C) and Cdk-activating kinase (Cak). (Nigg, 2001) PLK1 can phosphorylate 
Cdc25C and cause activation of the phosphatase in vitro, which suggests PLK1 may 
involve in the activation of Cdc2. (Roshak et al., 2000) Emerging studies have also 
described that nuclear translocation of Cdc25C can be mediated by PLK1 
phosphorylation. (Bahassi el et al., 2004; Toyoshima-Morimoto et al., 2002) 
Toyoshima-Morimoto et al. (2002) showed phosphorylation of Cdc25C by PLK1 at 
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Ser198, which was located in a nuclear export signal, promoted its nuclear 
translocation in vivo whereas a mutation that convert Ser-198 to alanine would abolish 
the translocation of Cdc25C to nucleus. Similar physiological observation has also 
been found on cyclin B1 where PLK1 phosphorylation leads to nuclear accumulation 
of cyclin B1. (Toyoshima-Morimoto et al., 2001)  However, contrary results have 
been reported as well that show no evidences for PLK1 in regulating the nuclear 
translocation of cyclin B1. (Jackman et al., 2003) Therefore, such discrepancies still 
await further clarifications.      
 
Although PLK1 plays important roles in S and G2/M phase of the cell cycle as 
described previously, its major physiological function lies in the M phase. Silencing 
studies on PLK1 show cells are only arrested after entry into mitosis but not earlier, 
indicating that PLK1’s functions in S and G2/M phases are less essential to cell cycle 
progression before mitosis. (Liu and Erikson, 2002; Seong et al., 2002; van Vugt et al., 
2004) Instead, the characteristic events when PLKs activities are impaired are usually 
associated with aberrant spindle formations and failed cytokinesis. (Ohkura et al., 
1995; Sunkel and Glover, 1988) Several evidences have implicated PLK1 in 
regulating the bipolar spindle formations during onset of mitosis. Centrosomal protein 
Ninein-like protein (Nlp) is dissociated from γ-tubulin and centrosomes upon 
phosphorylation by PLK1 and such dissociation is required for proper spindle 
formations to take place. (Casenghi et al., 2003) PLK1 also phosphorylates the 
microtubule stabilizing proteins TCTP and causes these proteins failed to stabilize 
microtubules, which will presumably increase the microtubules dynamics required 
during spindle formations. (Xie et al., 2005; Yarm, 2002) Other origins of PLKs have 
also showed to interact with proteins involved in spindle formation such as 
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Stathmin/Op18 in Xenopus laevis (Budde et al., 2001), and Abnormal spindle protein 
(Asp) in Drosophila melanogaster. (do Carmo Avides et al., 2001) 
 
Besides regulating the formations of spindle assembly, PLK1 has also been showed to 
localize to kinetochores during mitosis. (Arnaud et al., 1998) Kinetochores are 
proteinaceous structures where the spindle microtubules bind and the sites where 
motor proteins assemble to drive the movement of chromatids separation. Unattached 
kinetochores will signal the activation of the spindle checkpoint. (Cleveland et al., 
2003) APC/C is the main inhibitory target in the spindle checkpoint as it is 
responsible in separating sister chromatids by liberating separase from securin. 
(Musacchio and Hardwick, 2002) PLK1 contributes to the regulation of spindle 
checkpoint via a few ways, which is mainly to bring about the activation of APC/C. 
Firstly, Early-mitotic inhibitor (Emi1) is an inhibitor of APC/C and phosphorylation 
of Emi1 within the DSGxxS sequence by PLK1 generates a phospho-degron that 
promotes binding with Skp1-Cullin-F-boxβ-TRCP (SCFβ-TRCP) ubiquitin ligase 
complexes, leading to the destruction of Emi1 and thus liberating APC/C. (Moshe et 
al., 2004b)  
 
Secondly, when the spindle checkpoint is activated, an array of associated checkpoint 
proteins including Bub1, BubR1, Bub3, Mad1, Mad 2, and CENP-E will be activated 
to inhibit APC/C through direct interactions with Cdc20, an activator for APC/C. 
(Bharadwaj and Yu, 2004) PLK1 may directly regulate these components such as 
BubR1 (Matsumura et al., 2007) and possibly Mad2 (Eckerdt and Strebhardt, 2006) in 
order to prevent APC/C inhibition and promote mitosis progression. PLK1 can also 
interact with components of APC/C as showed in mouse PLK1 and in 
  xi
Schizosaccharomyces pombe Plo1 to bring about APC/C activation. (Golan et al., 
2002; Kotani et al., 1998) Lastly, PLK1 homologues have also been implicated in 
promoting sister chromatids separation in Saccharomyces cerevisiae and Xenopus 
Laevis. (Alexandru et al., 2001; Lee and Amon, 2003; Losada et al., 2002) A recently 
discovered spindle checkpoint associated protein known as PLK1-interacting 
checkpoint "helicase" (Pich) has been implicated in monitoring the tension developed 
between sister kinetochores. Its localization to kinetochores depends on the actions of 
Cdk1 and PLK1. Therefore, PLK1 may also involve in regulating the tension 
generated between sister kinetochores during mitosis via Pich. (Baumann et al., 
2007)Although much is still waiting to be discovered on the various functional roles 
of PLK1 in regulating the spindle checkpoint, its functions are indisputably essential 
in promoting cell cycle progression through mitosis.  
 
Studies in Schizosaccharomyces pombe have revealed PLKs roles in regulating 
septation, (Ohkura et al., 1995) which implied cytokinesis in mammalian cells can be 
also under the regulation of PLKs. Since impairment of PLKs activities in mammalian 
cells usually leads to mitotic arrest, it is therefore challenging to study PLKs’ roles in 
cytokinesis. (Barr et al., 2004) Still, there are few reports that provide some insights 
in this particular role of PLKs. For instance, overexpression of PLK1 will lead to 
generation of large cells that have multiple nuclei, which is consistent with failed 
cytokinesis. (Mundt et al., 1997) Phosphorylations of motor proteins that are part of 
the Dynein complex like Mitotic kinesin-like protein 2 (Mklp2) and 
Nuclear-distribution gene C (NudC) by PLK1 are crucial for cytokinesis as such 
phosphorylations are required to localize Mklp2 and NudC to the central spindle 
together with PLK1. Both Mklp2 and NudC can interact with PBD of PLK1, which 
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suggests that PLK1 may mediate their localization. (Aumais et al., 2003; Neef et al., 
2003; Nishino et al., 2006; Zhou et al., 2003) Another kinesin-related motor protein 
Pavarotti has also been showed to co-localize with PLK1. (Adams et al., 1998) Recent 
studies in Golgi dynamics during mitosis have also showed PLKs involvement in 
phosphorylation of a peripheral golgi protein Nir2 with Cdk1 providing the binding 
sites for PLK1. (Litvak et al., 2004)  
 
Polo-like Kinases and Cancers 
 
Transformation of normal cells to malignant cells requires acquisition of multiple 
genetic defects that eventually contribute to deregulated cells proliferation. 
(Vogelstein and Kinzler, 1993) Among these genetic defects, genes regulating the cell 
cycle are often implicated e.g., p53, Ras and Myc, of which the deregulation of these 
proteins will generally promote proliferation of cells. (Carnero, 2002) PLK1 is also a 
potent oncogene and its over-expression can transform NIH3T3 cells into developing 
tumors in nude mice. (Smith et al., 1997) Many tumors have reported 
over-expressions of PLK1 (Tab. II). In tumors such as non-small-cell lung cancer, 
colon cancer, heck and neck cancer, melanoma, bladder cancer and hepatoblastoma, 
PLK1 expressions have significant prognostic values. (Knecht et al., 1999; Knecht et 
al., 2000; Kneisel et al., 2002; Nogawa et al., 2005; Strebhardt et al., 2000; Takahashi 
et al., 2003; Wolf et al., 1997; Yamada et al., 2004) In addition, high expressions of 
PLK1 in melanoma and breast cancer correlate well to the metastatic potential of 
those tumors. (Ahr et al., 2002; Kneisel et al., 2002)  
 
It is therefore apparent that PLK1 is a potential cancer therapy target that can be 
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applied in a broad range of cancers. Indeed, several studies using short interfering 
RNA (siRNA) mediated silencing of PLK1 gene expressions in gastric cancer (Chen 
et al., 2006b; Jang et al., 2006), prostate cancer (Shaw and Ahmad, 2005), breast 
cancer (Spänkuch et al., 2007), bladder cancer (Nogawa et al., 2005) and other cancer 
cell lines (Guan et al., 2005; Liu and Erikson, 2003; Spänkuch et al., 2002) showed 
significant increases in apoptosis and tumors growth is impeded. In contrast, normal 
cells such as hTERT-RPE1, human retinal pigment epithelial cell line that stably 
expresses human telomerase reverse transcriptase (hTERT), MCF10A, spontaneous 
immortalized human diploid breast epithelial cells and HMEC, human mammary 
epithelial cells exhibit no increased apoptosis although with reduced rates of mitosis 
when PLK1 expressions are silenced. (Liu et al., 2006; Spänkuch et al., 2002) These 
studies support PLK1 as a suitable anti-cancer target and perhaps with only minor 
side effects. In fact, two highly selective small molecule inhibitors of PLK1: BI 2536 
and ON01910 are undergoing clinical trials currently. (Gumireddy et al., 2005; Mross 
et al., 2005b; Steegmaier et al., 2007a; Steegmaier et al., 2007b)  
 
Hepatocellular carcinoma (HCC) is the 5th common solid tumor cancer in the world 
and is ranked 3rd in term of mortality according to GLOBALCAN 2002. (Ferlay et al., 
2004) Chronic Hepatitis B and C are two of the main etiological agents for HCC, 
while non-alcoholic steatohepatitis (NASH) begins to receive attention as one of the 
high risk factors in HCC. (Bruix and Sherman, 2005; El-Serag and Rudolph, 2007) 
HCC is usually preceded by chronic liver injuries such as hepatitis or cirrhosis that 
may persists for a period of 20-40 years before finally developing into HCC. During 
the long latent period, hepatocytes at site of lesion gradually acquire genetic 
alterations to become dysplastic and eventually malignant. (Thorgeirsson and 
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Grisham, 2002) The exact underlying mechanism of HCC pathogenesis is still 
remained largely unknown although some hypothesized that the high proliferation rate 
of hepatocytes during early phase of chronic liver injuries can create a favorable 
condition for hepatocytes to acquire mutations. It is suggested that senescence of 
hepatocytes due to telomere shortening as a result of enhanced proliferation rate will 
greatly reduce the number of functional hepatocytes. Minor population of these 
senescent hepatocytes may escape apoptosis and enter a state of genomic instability 
that may promote acquisition of oncogenes. In addition, the inflammatory state of the 
liver will probably promote tumorigenesis by releasing arrays of tumor promoting 
factors such as growth factors, chemokines or cytokines. (El-Serag and Rudolph, 
2007)  
 
Surgical treatments including partial hepatectomy and orthotopic liver transplantation 
remain as the most prospective cures for HCC patients because the effectiveness of 
conventional chemo- or radiotherapy is lacking. While liver transplantation remains 
as an limited option, resected patients on the other hand faced with poor prognosis 
where about 75% of the HCC patients that had undergone resections suffered from 
recurrence (Bruix and Llovet, 2002; Llovet et al., 1999). Considering the high 
mortality rate of HCC and the very limited effective treatments available, it is 
therefore imperative to embark on other therapy options such as gene therapy that 
may harbor great potentials. Hence, it is interesting to examine PLK1 expressions in 





Future Prospects of Polo-like Kinases 
 
PLKs have started to emerge as another major key player in cell cycle besides the 
well-known cell cycle dependent kinases and their associated cyclins. Potential PLKs’ 
downstream substrates and upstream regulators discovery will further enhance our 
understanding in the molecular mechanism of PLKs in regulating mitosis, especially 
with the helps from the crystallized structure of the PBD and the recently available 
crystallized kinase domain of PLK1. (Kothe et al., 2007) Localization of PLK1 to 
kinetochores and being able to phosphorylate kinetochores that are not under tension 
(Ahonen et al., 2005; Wong and Fang, 2005) as well as the discovery of Pich have 
provided important insights in the signaling pathways that interpret tension changes at 
kinetochores, which can be channeled to regulate the spindle checkpoint instead. 
Indeed, PLKs still have many novel functions that await future explorations and such 
discoveries will definitely enhance the understandings on the intricate regulation of 
cell cycle. The spotlight is now on PLKs as the next potential therapeutic targets in 
gene therapy that can be applied onto various kinds of cancers. Encouraging results 
from silencing experiments on different cancers implied that PLKs inhibitors with 
high potency and efficacy can be engineered and used as anti-cancer drugs. (Eckerdt 
et al., 2005) With the increasing research interests in PLKs, one can anticipate more 




LITERATURE REVIEW: LIST OF TABLE AND FIGURE 
 
Table I: Polo-like kinase (PLK) in different organisms. 
 
Organism PLK Reference 
Saccharomyces cerevisiae Cdc5 (Kitada et al., 
1993) 
Schizosaccharomyces pombe Plo1p (Ohkura et al., 
1995) 
Caenorhabditis elegans Plc1, Plc2, Plc3 (Chase et al., 2000; 
Ouyang et al., 
1999) 
Drosophila melanogaster Polo (Llamazares et al., 
1991; Sunkel and 
Glover, 1988) 
Xenopus laevis Plx1, Plx2, Plx3 (Duncan et al., 
2001; Kumagai and 
Dunphy, 1996) 




(Clay et al., 1993; 
Fode et al., 1994; 
Golsteyn et al., 
1994; Hamanaka et 
al., 1994; Karn et 
al., 1997; Lake and 
Jelinek, 1993; Li et 
al., 1996; Ouyang 
et al., 1997; 
Simmons et al., 
1992) 
 
Cdc, cell division cycle; Plo (Polo); Plc (Polo-like kinase of C. elegans); Plx 
(Polo-like kinase of X. laevis); Snk (serum-inducible kinase); Fnk 
(fibroblastgrowth-factor-indiucible kinase); Prk (proliferation-related kinase); Sak 














Table II: Polo-like kinase 1 overexpression in various tumors.  
 
Tumor Reference 
Non-small-cell lung cancer (Wolf et al., 1997) 
Gliomas (Dietzmann et al., 2001) 
Head and neck cancer (Knecht et al., 1999; Knecht et al., 2000) 
Ovarian cancer (Takai et al., 2001a; Weichert et al., 2004a) 
Breast cancer (Ahr et al., 2002; Weichert et al., 2005b; Wolf et al., 
2000) 
Colorectal cancer (Macmillan et al., 2001; Takahashi et al., 2003; 
Weichert et al., 2005a) 
Endometrial cancer (Takai et al., 2001b) 
Esophageal and gastric cancer (Tokumitsu et al., 1999) 
Pancreatic cancer (Gray et al., 2004; Weichert et al., 2005c) 
Prostate carcinoma (Weichert et al., 2004b) 
Papillary carcinoma (Ito et al., 2004) 
Hepatoblastoma (Yamada et al., 2004) 
Non-Hodgkin lymphoma (Mito et al., 2005) 
Melanoma (Kneisel et al., 2002; Strebhardt et al., 2000) 
Bladder cancer (Nogawa et al., 2005) 










Figure I: Structure and domains of Polo-like kinase (PLK). Key residues involved in 






Polo-like kinase 1 (PLK1) plays important roles in the progression of cell cycle, 
especially for cells to transit from anaphase to telophase during mitosis. PLK1 is 
overexpressed in various cancers and has significant prognostic values. In this study,  
PLK1 gene expression was evaluated in Hepatocellular carcinoma (HCC) and found 
to be overexpressed frequently in HCC patients. Gene silencing technology utilizing 
short interfering RNA (siRNA) was subsequently employed to study the potential of 
PLK1 to be the therapeutic target in treating HCC. The results from this study showed 
significant anti-proliferative effect in a human hepatoma cell line Huh-7 that 
overexpressed PLK1 when PLK1 gene expression was silenced. Silencing of PLK1 
gene expression also induced caspase-independent apoptosis pathway in Huh-7 with 
endonuclease G identified as the potential main apoptotic effector. Forkhead box M1 
(FOXM1) gene expression was found to correlate positively to the gene expression of 
PLK1 within the same patient cohort in this study. However, silencing of FOXM1 
gene expression did not affect the gene expression of PLK1 in Huh-7 suggesting that 
there are other undefined transcription factors that regulate PLK1 gene expression in a 
compensatory or synergistic way. The therapeutic potential of PLK1 was further 
examined in nude mice that were transplanted subcutaneously with Huh-7 in matrigel. 
Intratumor injection of siRNA targeted at PLK1 had successfully impeded the tumor 
growth. In conclusion, PLK1 is overexpressed in HCC and silencing of PLK1 gene 
expression produces anti-tumor effects that make PLK1 to be the potential therapeutic 





Hepatocellular carcinoma (HCC) is the 5th common solid tumor cancer in the world 
and is ranked 3rd in term of mortality according to GLOBALCAN 2002. (Ferlay et al., 
2004) African and Asian countries such as China and South Korea have very high 
incidence rates of HCC, which are also countries that are endemic for Hepatitis B. 
(El-Serag and Rudolph, 2007) Chronic Hepatitis B and C are the two most 
well-known risk factors for HCC among other risk factors such as heavy alcohol 
intake and aflatoxin poisoning. (Bruix and Sherman, 2005) Non-alcoholic 
steatohepatitis (NASH) presents another unconventional risk factor that may be 
resulted from diabetes mellitus and obesity although such correlations still require 
further supporting studies. (El-Serag and Rudolph, 2007)  
 
The exact underlying mechanism of pathogenesis of HCC is still elusive. It has a long 
latent period of about 20 to 40 years while the patients may be suffering from chronic 
liver injuries such as hepatitis or cirrhosis. It is suggested that to compensate the liver 
injuries, hepatocytes undergo enhanced proliferation and subsequently enter 
senescence due to telomeres shortening. However, the chronic inflammatory state of 
the liver has resulted in arrays of growth factors, chemokines and cytokines being 
secreted thus creating a niche that favor the proliferation of hepatocytes even in 
senescence state. Such condition will eventually exhaust the telomeres completely and 
causes genomic instability. It is possible that along these series of events, hepatocytes 
can acquire the necessary genetic alterations and consequently become malignant. 
(El-Serag and Rudolph, 2007; Thorgeirsson and Grisham, 2002)  
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Orthotopic liver transplantation remains to be the most curative treatment for HCC 
patients especially for those who are having unresectable HCC. However, it is very 
limited by the availability of suitable donors. While conventional chemo- or 
radiotheraphy lacks its effectiveness in treating HCC due to resistances, surgical 
resections or local ablations of HCC are suffered from poor prognosis as depicted by 
the low 5-year survival rates of 17% to 53%. (Chen et al., 2006a; Yamamoto et al., 
1996) Another main concern for resected HCC patients is the possibility of recurrence 
that can happen in about 75% of the resected HCC patients. (Bruix and Llovet, 2002; 
Llovet et al., 1999) The lack of effective treatment options prompts for other therapy 
alternatives that can provide better treatment outcomes for HCC patients. A genomic 
approach to study HCC may be able to tackle this task and has actually beginning to 
show promising results.  
 
Recent genomic studies in HCC have helped in deciphering the possible underlying 
molecular mechanisms that lead to HCC. (Pang et al., 2006; Thorgeirsson and 
Grisham, 2002) Many genes are identified to be associated with HCC and some have 
showed high prognostic or therapeutic potentials. (Avila et al., 2006) For instance, 
tumor suppressor gene p53 is one of the genes that is mutated in about 24% to 69% of 
HCC (Beerheide et al., 2000; Osada et al., 2004; Soini et al., 1996) and is associated 
with poor survival. (Hayashi et al., 1995; Sugo et al., 1999) Re-introducing wild type 
p53 gene into p53 knockout HCC cells using retroviral vector is showed to be able to 
prevent tumor growth and increases the sensitivity against chemotherapy. (Xu et al., 
1996) While the efficiency of p53 gene delivery in a clinical setting still requires 
further technical optimization, it nonetheless provides insights in the potentials of 
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gene therapy. (Warren and Kirn, 2002) 
  
By using the available published microarray data on HCC, (Chen et al., 2002; Lee et 
al., 2004; Okabe et al., 2001) ten gene candidates that showed up-regulation were 
chosen for gene expressions analysis using real-time reverse transcription (RT) 
quantitative PCR on 56 paired tumor/non-tumor liver samples from resected HCC 
patients who are HBV-positive. Among these ten gene candidates, Polo-like kinase 1 
(PLK1) was chosen to be further evaluated using short interference RNA (siRNA) 
technology to assess its potential as a therapeutic gene target in HCC treatment. PLK1 
is a cell cycle kinase with unique structural properties that involves in M-phase and 
has been showed to be over-expressed in various other tumors. (Takai et al., 2005)
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MATERIALS AND METHODS 
 
Patients and Samples 
 
Tumor and surrounding non-tumor liver tissues were obtained from 56 primary HCC 
patients who underwent liver resection in National University Hospitals from 1998 to 
2002. All patients were identified to be Hepatitis B positive and of Asian ethnicity. 
The patients were from 49 males and 7 females of aged 32 to 82 years (mean, 56 
years). The tumors were histologically classified by Department of Pathology, 
National University of Singapore. The study was approved by the National University 
of Singapore Institutional Review Board and National Healthcare Group Domain 
Specific Review Boards. Informed consents were obtained from every patient on the 
use of the tissues. The human hepatoma cell lines HepG2 was obtained from 
American Type Culture Collection (ATCC number: HB-8065), Huh-7 was from 
Japanese Collection of Research Bioresources Cell Bank (Cat# JCRB0403), and 
HepG2.215 was kindly provided by Dr. Acs (Mt. Sinai Medical College, New York, 
NY). HepG2 and Huh-7 were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 0.1 mM sodium pyruvate, 0.1 mM L-glutamine, 0.1 mM 
non-essential amino acids, 10% fetal calf serum, and 1X antibiotic-antimycotic 
solution (Invitrogen, Carlsbad, CA). HepG2.215 was cultured in similar media with 
0.4 mg/mL G418 (Sigma-Aldrich, St Louis, MO) added. All cell lines were 





RNA Extraction and cDNA Synthesis 
 
Total RNA was extracted from cell lines or tissues using RNeasy Mini kits (Qiagen, 
Hilden, Germany) or Trizol (Invitrogen) respectively according to the manufacturers’ 
protocols. Total RNAs from patients’ tissues were kindly prepared and provided by Dr. 
Aung, M.O. (National University Hospital, Singapore). Reverse transcription was 
carried out in 26 μL aliquot of solution, containing 5 μg of total RNA, 2.5 ng Oligo 
d(T)18 and RNase-free water, which was then put on 15 minutes incubation at 72oC in 
a thermalcycler. After 10 minutes cooling at 4oC, 24 μL of the RT-enzyme mixtures 
containing 5 μL 10 mM dNTPs, 5 μL 0.1 M DTT, 10 μL 5X First-Strand Buffer, 2 μL 
SuperScript™ II Reverse Transcriptase (Invitrogen) and 2 μL Recombinant RNasin 
Ribonuclease Inhibitor (Promega, Madison, WI) was added to a final 50 μL total 
solution. The mixture was then incubated for 90 minutes at 42oC followed by 15 
minutes incubation at 72oC and was subsequently cooled to 10oC.  
 
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
All primers and probes for the 10 target genes were from TaqMan Gene Expression 
Assays (Applied Biosystems, Foster City, CA). In brief, 20 μL reaction was set up 
containing 4 μL cDNA, 10 μL 2X TaqMan Universal PCR Master Mix (Applied 
Biosystems), 1 μL  20X TaqMan Gene Expression Assay Mix of corresponding 
target gene, 1 μL 20X Human Hypoxanthine-guanine phosphoribosyltransferase  
Endogenous Control (Applied Biosystems) (de Kok et al., 2005) and 4 μL RNase-free 
water. The reaction was run on ABI Prism 7000 Sequence Detection System (Applied 
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Biosystems) with the following profile: 1 cycle at 50°C for 2 minutes, 1 cycle at 95°C 
for 10 minutes, then 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. 
No-template control and TaqMan Control Total RNA (Human) (Applied Biosystems) 
as reference control were also included where applicable. Relative quantification was 
done using 2-∆∆Ct method.  
 
Short Interfering RNA (siRNA) Transfection 
 
siRNA targeting human PLK1 (si-PLK1) and FOXM1 (si-FOXM1) were from 
siGENOME On-TargetPlus Set of 4 duplex (Dharmacon, Chicago, IL) and On-Target 
plus siCONTROL Non-targeting pool (si-NT) (Dharmacon) was used as negative 
control. The mixture containing four siRNA duplexes was transfected into cells using 
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according to the 
manufacturer’s protocol. No-treatment and transfection-reagent-only controls were 
also included where suitable. Transfection period was 48 hours for any assays or tests 
unless otherwise specified.  
 
Western Blot Analysis 
 
Cells were lysed using Complete Lysis-M (Roche Applied Science, Indianapolis, IN) 
according to the manufacturer’s protocol. The protein concentration was determined 
using BCA Protein Assay Kit (Pierce, Rockford, IL). Protein (30 μg) was mixed 1:1 
with Laemmli sample buffer (Bio-rad Laboratories, Hercules, CA) supplemented with 
5% β-mercaptoethanol and was heated at 95°C for 5 minutes followed by a 5 minutes 
cool down on ice. The sample was then loaded onto a 10% Tris-HCl Ready Gel 
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(Bio-rad) and subsequently electrotransferred to a Hybond™-P polyvinylidene 
difluoride membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). The 
membrane was blocked for an hour at room temperature with 5% Blotting-Grade 
Blocker, non-fat dry milk (Bio-rad). After blocking, the membrane was incubated 
with mouse anti-human PLK1 (F-8) antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) at 1:500 for an hour at room temperature followed by incubation with Cruz 
Marker Compatible goat anti-mouse IgG  antibody (Santa Cruz) at 1:50 000 for an 
hour at room temperature. The reaction was detected using ECL plus system 
(Amersham) and developed using Hyperfilm ECL (Amersham). Mouse anti-human 
β-actin (C4) antibody (Santa Cruz) diluted at 1:10 000 was used as loading control. 
Blots were analyzed with Quantity One (Bio-rad).  
 
Cell Proliferation Assays  
 
For both assays, 2500 cells were seeded overnight in 96-well tissue culture plate 
followed by the indicated transfections or treatments in the following day. Assays 
were carried out 48 hours after transfections or treatments. MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)- 
2H-tetrazolium) assay was performed using CellTiter 96 AQueous Non-Radioactive 
Cell Proliferation Assay (MTS) (Promega) according to the manufacturer’s protocol. 
In brief, 20 μL mixture of MTS:PMS (phenazine methosulfate) in the ratio of 20:1 
was added directly to a 96-well containing 100 μL media and the absorbance of 
formazan formed was subsequently measured at 490nm after 2 hours of incubation at 
37oC. BrdU (5-Bromo-2-Deoxyuridine) assay was performed using Cell Proliferation 
ELISA, BrdU (chemiluminescent) (Roche) according to the manufacturer’s protocol. 
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In summary, cells were incubated with BrdU for 2 hours at 37oC followed by fixation 
and denaturation to allow binding of anti-BrdU antibody that was peroxidase 
conjugated. Substrates solution was added after 90 minutes of anti-BrdU incubation 
and luminescence was measured with luminometer.  
 
Immunofluorescence Imaging 
Cells were cultured on Lab-Tek II 2-chambered glass slide (Nunc, Rochester, NY). 
Twenty-four hours after siRNA transfection, the cells were fixed in 70% pre-cooled 
ethanol at -20oC overnight or in 4% buffered paraformaldehyde for 30 minutes at 4oC. 
The cells were then permeabilized with 0.5% Triton X-100 in phosphate-buffered 
solution for 10 minutes followed by blocking in 2% bovine serum albumin for 10 
minutes. The cells were incubated with primary antibody diluted at 1:100 for an hour 
at room temperature followed by an hour incubation at room temperature with 
FITC-conjugated secondary antibody diluted at 1:400. The cells were subsequently 
mounted using Vectashield with 4’,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, Burlingame, CA) for nuclei counterstainig. Primary antibodies used 
were fluorescein isothiocyanate (FITC)- conjugated mouse anti-α-tubulin antibody 
(clone DM1A) (Sigma-Aldrich), goat polyclonal anti-human endonuclease G (Santa 
Cruz) and goat polyclonal anti-human apoptosis-inducing factor. (Santa Cruz); 
secondary antibody used was donkey anti-goat IgG-FITC (Santa Cruz). Fluorescence 
images were captured using Olympus Fluoview FV500 or BX60F5. (Olympus, Center 
Valley, PA) 
 




Chromosome fragmentation was detected using Cell Death Detection ELISAPLUS 
(Roche) according to the manufacturer’s protocol. In brief, 2500 cells were seeded in 
96-well tissue culture plates overnight before transfections or treatments. After 48 
hours of transfections or treatments, the cells were lysed and the supernatant were 
transferred to a streptavidin-coated microplate and incubated with a mixture of 
anti-histone-biotin and anti-DNA-peroxidase for 2 hours at room temperature. 
Unbound antibodies were washed away subsequently and the amount of peroxidase 
retained in the immunocomplex was photometrically determined with ABTS as the 
substrate with a spectrophotometer. Thapsigargin (Sigma-Aldrich) treatment was used 
as positive control.  
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was 
carried out after 24 hours of transfection using DeadEnd Fluorometric TUNEL system 
(Promega) according to the manufacturer’s protocol. In summary, 100 000 cells were 
cultured on Lab-Tek II 2-chambered glass slide (Nunc, Rochester, NY) overnight and 
transfections were subsequently performed for 24 hours. Cells were fixed in 4% 
formaldehyde in PBS for 25 minutes at 4°C followed by permeabilization in 0.2% 
Triton X-100 in PBS for 5 minutes. Cells were incubated in equilibration buffer for 10 
minutes and labeling solution was then added for 60 minutes at 37°C in a humidified 
chamber. Reaction was stopped afterwards with 2X SSC and nuclei were 
counterstained with DAPI. Fluorescence images were captured using Olympus 
BX60F5 (Olympus).  
 
Caspase-3 activity assay (Roche) was performed according to the manufacturer’s 
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protocol. In brief, after 48 hours of transfection on 2500 cells seeded on 96-well tissue 
culture plates, lysis buffer was added and supernatant was subsequently transferred to 
a microplate that was coated with anti-caspase-3 for 1 hour at 37oC. Substrate solution 
was then added for 2 hours at 37oC after a washing step. Fluorescence intensity was 
measured afterwards with a fluorescence reader with an excitation filter 370-425 nm 
and emission filter 490–530 nm.  
 
 
Caspase Inhibition Assay 
 
Cells were transfected with siRNA in the presence of cell permeable pan caspase 
inhibitor Z-VAD-FMK (Sigma-Aldrich) at 100 μM for 48 hours. Cells proliferations 
were subsequently determined with MTS assay. Camptothecin (Sigma-Aldrich) at 5 
μM was used to induce apoptosis in HepG2. For camptothecin treatment, HepG2 cells 
were incubated with caspase inhibitor for an hour before camptothecin was added and 
remained till the end of incubation. Equal amount of DMSO was used in negative 
control where appropriate.    
 
In Vivo Nude Mice Experiment 
 
Nude mice were transplanted subcutaneously with two millions Huh-7 cells in 100 μL 
Matrigel (Sigma-Aldrich). Treatment was started one week after the transplantation. 
Eighteen tumor-bearing nude mice were divided equally into group that received 
si-PLK1 treatment, group that received si-NT treatment, or group that received no 
treatment respectively. Treatment groups received intratumor injections of 1 nmol 
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siRNA coupled with Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) 
every alternate day. No-treatment group was injected with saline instead. Tumor sizes 
were recorded before treatments were given and calculated by the formula: volume 
(mm3) = (width)2 x length/2. Animal experiments were carried out in compliance with 
the guidelines of the Laboratory Animals Centre, National University of Singapore 
and were approved by the National University of Singapore Institutional Animal Care 
and Use Committee.  
 
Polo-like Kinase 1 Gene Sequences Analysis 
 
PLK1 genes from selected patients were sequenced using VariantSEQr resequencing 
system, (Resequencing set ID version: RSS000014009_02, Applied Biosystems) and 
analyzed using SeqScape v2.5 (Applied Biosystems). Patients’ DNAs were kindly 
provided by Dr. Aung, M.O. (National University Hospital, Singapore).  Four 
patients (Patient ID 96, 104, 111, 131) with relative PLK1 expression of 49.5 ± 9.2 
(mean ± SEM) were grouped as having higher PLK1 gene expression. Three patients 
(Patient ID 47, 79, 149) with relative PLK1 expression of 1.1 ± 0.1 were grouped as 





Statistical analysis was carried out using Microsoft Excel or SPSS. p value of less 
than 0.05 was deemed significant. All data was expressed as mean ± standard error of 





Selected Genes Expressions in Human Hepatocellular Carcinoma Patients  
 
Gene expression levels of the ten selected target genes in HCC were showed in Table 
1. Six of the targeted genes showed significant up-regulation in HCC, i.e. PLK1, 
FOXM1, PTTG1, USP21, RCN2, DUSP12, and USP1. Up-regulation of PLK1 gene 
expression in HCC was the highest in this study, which is 11 times higher than the 
surrounding non-HCC tissues, followed by FOXM1 and PTTG1. This implied that 
PLK1 might play an important role in the oncogenesis of HCC and therefore was 
subjected to further evaluation using silencing experiments. Correlations between the 
gene expression of PLK1 and various clinicopathological parameters revealed no 
significant associations in this study (Tab. 2). FOXM1 and PTTG1 genes expressions 
were also moderately up-regulated in HCC and recent reports had showed that PTTG1 
was over-expressed in HCC and associated with angiogenesis and poor prognosis. 
(Fujii et al., 2006; Su et al., 2006)  
 
Selection of Human Hepatoma Cell Line  
 
In order to select the suitable human hepatoma cell line for PLK1 gene silencing 
experiments, Huh-7, HepG2 and HepG2.215 were evaluated for their PLK1 gene 
expressions using real-time quantitative RT-PCR (Tab. 3). HepG2 was established 
from HCC in a 15 year-old male Caucasian, and Huh-7 was established from 
well-differentiated HCC in a 57 year-old male Japanese. HepG2.215 was engineered 
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to harbor the HBV genome and expressed associated HBV proteins constitutively. 
Among these, Huh-7 expressed the highest level of PLK1 and thus was selected as the 
model cell line for further experiments. PLK1 gene expressions in normal human 
adult and fetal liver tissues were also quantified and their expressions were 
significantly lower than the hepatoma cell lines (Tab. 3). It was interesting to note that 
normal fetal liver had higher PLK1 gene expression as compared to normal adult liver. 
This was probably attributed to the higher proliferation rate of fetal liver during fetal 
development, which bore some similarity to the unregulated proliferative nature of 
tumor cells.  
 
Gene Silencing of Polo-like Kinase 1 Reduced Huh-7 Proliferation 
 
MTS and BrdU assays were used to measure the gene silencing effects of PLK1 on 
Huh-7 proliferation. Proliferation of si-PLK1 transfected Huh-7 was reduced by an 
average of 65% when compared to the si-NT transfected Huh-7 in MTS assay (Fig. 1). 
Similar observation was also found in BrdU assay with 93% reduction in Huh-7 
proliferation in average. (Fig. 2) Both assays showed no significant differences among 
si-NT transfected Huh-7, Huh-7 transfected with transfection reagent only and Huh-7 
without any treatment, indicating that differences observed in si-PLK1 transfected 
Huh-7 were not affected by the treatment of siRNA and the transfection reagent itself. 
The concentration of siRNA was found to have no prominent effect on the degree of 
reduction in cell proliferation of Huh-7 in both assays. Significant anti-proliferation 
effect could probably be achieved with si-PLK1 concentration that was less than 1 
nM.    
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Gene Silencing of Polo-like Kinase 1 by Short Interference RNA Is Effective 
 
In order to confirm the reductions observed in both MTS and BrdU assays were 
indeed resulted from silencing PLK1 gene expression in Huh-7, PLK1 gene and 
protein expressions were evaluated. PLK1 gene expressions were greatly reduced as 
measured by real-time quantitative RT-PCR (Fig. 3). Even at 1 nM si-PLK1, gene 
expression of PLK1 was reduced by 83% in average. This indicated that the potency 
of si-PLK1 was high and the transfection procedure was equally effective. At higher 
si-PLK1 concentrations of 50 nM and 100 nM, the reduction in gene expression was 
significantly higher than 1 nM si-PLK1 but there was not much difference between 
these two si-PLK1 concentrations. To further verify whether the reduction in PLK1 
gene expression was also translated into protein expression, PLK1 protein expression 
was evaluated using western blot (Fig. 4). At 50 nM si-PLK1, PLK1 protein 
expression in Huh-7 was greatly reduced by 95% when compared to the si-NT 
transfected Huh-7. The PLK1 gene and protein expression results in Huh-7 
transfected with si-PLK1 collectively showed that the si-PLK1 used in this study was 
sufficiently effective.. Differences observed in si-PLK1 transfected Huh-7 were also 
not affected by the siRNA treatment and the transfection reagent as Huh-7 transfected 
with si-NT, transfection reagent only or without treatment showed no significant 
differences. Specificity of si-PLK1 was warranted by the manufacturing company 
based on proprietary chemical modifications and bioinformatics. 
 
Gene Silencing of Polo-like Kinase 1 Arrested Huh-7 in Mitosis    
 
A cellular hallmark feature of PLK1 dysfunction was the failure to complete mitosis 
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due to aberrant spindle formation that resulted in multi-nuclei daughter cells that 
failed to separate. (Ohkura et al., 1995; Sunkel and Glover, 1988) Huh-7 transfected 
with 50 nM si-PLK1 was stained with FITC-conjugated mouse anti-α-tubulin 
antibody and counterstained with DAPI for nuclei in order to detect this phenomenon 
(Fig. 5). The fluorescence images captured clearly showed bi-nuclei Huh-7 cells that 
were still attached to each other while Huh-7 cells treated with si-NT were completing 
mitosis with functional spindle assembly.  
 
Gene Silencing of Polo-like Kinase 1 Induced Apoptosis that Was Caspase 
Independent in Huh-7 
 
Silencing of PLK1 in Huh-7 showed significant reduction in proliferation and 
therefore it was important to determine whether apoptosis was induced. Nuclear 
fragmentation was one of the key events in apoptosis and this could be measured by 
using antibody that targeted mono- and oligosomes in the cytoplasmic fraction of 
Huh-7 cells lysates that had been cleared from necrotic cells. Apoptotic events in 
Huh-7 transfected with si-PLK1 were 3-folds higher when compared to the si-NT 
transfected Huh-7 (Fig. 6). In addition, TUNEL staining of si-PLK1 transfected Huh-7 
cells (Fig. 7) also revealed nuclear fragmentation in apoptotic cells as early as 24 
hours after transfection.   
 
Caspase-3 activity assay was carried out (Fig. 8) and intrigued to find that caspase-3 
activation in si-PLK1 transfected Huh-7 was absent in the first 12 hours and 24 hours 
after transfection. This observation contrasted the result from the TUNEL assay, 
which showed that nuclear fragmentation was evident after 24 hours of transfection. 
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This result suggested that besides caspase activation, si-PLK1 transfected Huh-7 
might undergo apoptosis without the requirement of caspase activation. A cell 
permeable pan caspase inhibitor Z-VAD-FMK was subsequently applied to validate 
the requirement of capsases in apoptosis induction in si-PLK1 transfected Huh-7. By 
using MTS cell proliferation assay as the functional end-point indicator for apoptosis, 
pan caspase inhibitor was showed to be unable to prevent the reduction in 
proliferation of Huh-7 transfected with si-PLK1 (Fig. 9). This was particularly 
contrasted by HepG2 that was treated with camptothecin where the pan caspase 
inhibitor had successfully protected those cells from apoptosis (Fig. 9). The results 
thus demonstrated that apoptosis induced by silencing of PLK1 gene expresison in 
Huh-7 was independent of caspase activation. Two mitochondrial exclusive 
pro-apoptotic proteins, Endonuclease G (EndoG) and Apoptosis-inducing factor (AIF) 
were reported to be involved in caspase independent apoptosis pathway. (Niikura et 
al., 2007) As showed in Figure 10, si-PLK1 transfected Huh-7 cells were found to be 
positively stained with EndoG but not with AIF. Therefore, EndoG was probably the 
main apoptotic effector in this particular apoptosis pathway.  
 
Polo-like Kinase 1 Gene Sequences Analysis and Association with Forkhead Box M1   
 
Considering the prominent anti-proliferative effects by silencing PLK1 gene 
expression in Huh-7, it was evident that PLK1 over-expression was likely to play a 
crucial role in tumorigenesis of HCC. It was interesting to examine and compare the 
gene sequences of PLK1 between HCC patients with higher and lower level PLK1 
gene expressions to discover any mutations that might affect PLK1 expressions. 
PLK1 gene sequences from four patients that had higher PLK1 gene expressions and 
  18
three patients that had lower PLK1 gene expressions were analyzed and found no 
significant mutations when compared to the reference sequences. This result 
suggested that mutations within the PLK1 gene might not be responsible in affecting 
the gene expression. Nevertheless, the available sample size was relatively small and 
thus limited the chance of discovering significant mutations.  
 
Recent studies had suggested that PLK1 could be positively regulated by transcription 
factors from members of the Forkhead transcription factors (FKH-TF) such as 
FOXM1. (Martin and Strebhardt, 2006) Coincidentally, FOXM1 was also one of the 
up-regulated genes in the HCC patients cohort in this study with over 50% of the 
patients had at least 4 times higher FOXM1 gene expressions (Tab. 1) in their tumors. 
Non-parametric correlation tests on the gene expression levels of PLK1 and FOXM1 
in this cohort of HCC patients revealed significant positive correlations (Fig. 11). This 
provided further indication that gene expression levels of PLK1 and FOXM1 might be 
tied up in certain ways. It was thus of interest to examine whether silencing of the 
FOXM1 gene expression would bring about an anticipated decrease in the gene 
expression of PLK1. Intriguingly, although FOXM1 gene expression was effectively 
silenced in Huh-7, there was no significant reduction in PLK1 gene expression at all 
(Fig. 12). The result was complemented by MTS cell proliferation assay where Huh-7 
proliferation was not affected across increasing concentrations of si-FOXM1 (Fig. 12). 
The results thus suggested that albeit FOXM1 might possess positive regulatory 
function on PLK1 gene expression, its absence would not severely affect PLK1 gene 
expression. This probably implied that its function might be redundant and could be 
readily compensated by other transcription factors that had yet been discovered. 
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In Vivo Nude Mice Experiment 
 
Huh-7 were subcutaneously transplanted into the flanks of nude mice and were 
allowed to develop into HCC tumors. These tumors served as the test bed to evaluate 
the anti-tumor effect of targeting PLK1 by si-PLK1 in vivo. The transplanted tumors 
followed a typical growth curve that is slow at the beginning of treatment period, 
which signified an adaptation phase but became more aggressive at later stage when 
sufficient tumor mass was gained. The tumor volumes between si-PLK1 and si-NT 
groups became significantly different starting from day-11 after five treatments (Fig. 
13A). The growth of tumors that were treated with si-PLK1 was slower than the 
tumors treated with si-NT. At the end of the treatment period, tumor volumes in 
si-PLK1 treatment group were about 33% smaller than those tumors in si-NT group 
(Fig 13). Although si-PLK1 treatment was not able to fully induce tumor recession, it 
was able to impede the growth of the tumors. Real-time PCR quantification was 
subsequently performed on the tumors collected to check for PLK1 gene expressions. 
PLK1 gene expressions in si-PLK1 group (3.84±0.16; mean) showed a 15% reduction 
compared to the si-NT group (4.54±0.15). The results had inevitably further 





PLK1 gene expression was over-expressed in majority of the HCC patients in this 
study, suggesting that PLK1 might have roles in the tumorigenesis of HCC. No 
significant correlation was evident between PLK1 gene expression and the available 
clinicopathological parameters i.e., age, sex, histological type of tumor, cirrhosis, or 
pathological TNM (tumor, node, metastasis) in this study cohort. However, one report 
found that PLK1 expression was significantly correlated with preoperative serum 
alpha-fetoprotein level and higher recurrence rate in HCC patients. (Chen et al., 2007) 
Therefore, PLK1 expression could have important prognostic value in HCC patients 
especially in predicting recurrence, which is one of the main concerns for resected 
HCC patients. 
 
PLK1 could be a potential target in treating HCC as demonstrated in this study using 
siRNA technology to silence the gene expression of PLK1 in a human hepatoma cell 
line Huh-7. Silencing of PLK1 in Huh-7 managed to reduce cell proliferation in 
Huh-7 by a significant percentage and impeded tumor growth in nude mice. However, 
the PLK1 reduction observed in tumors from nude mice that were treated with 
intratumor injection of si-PLK1 was not at similar efficiency as observed in Huh-7 in 
vitro. This discrepancy could be rationalized by the fact that delivery of siRNA into 
tumor is still remained inefficient and thus poses as a bottleneck in the clinical 
application of siRNA. Nevertheless, various new siRNA delivery technologies such as 
nanotechonology are being developed currently to circumvent this problem in order to 
finally able to use siRNA efficiently in treating patients. The anti-proliferative and 
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anti-cancer effects of silencing PLK1 in Huh-7 found in this study agreed with similar 
reports found on other human cancer cell lines e.g., breast cancer, lung cancer, 
prostate cancer and esophageal cancer. (Bu et al., 2008; Reagan-Shaw and Ahmad, 
2005; Spankuch-Schmitt et al., 2002) PLK1 is therefore a promising gene candidate 
to be targeted in treating not only HCC but in other solid tumors as well. The 
requirement of PLK1 in the tumorigenesis in HCC and other cancers signifies its 
critical role for cancer cells to proliferate. Over-expression of PLK1 might help to 
inactivate the spindle checkpoint persistently by targeting early-mitotic inhibitor 
(Emi1), which is an inhibitor of anaphase promoting complex/cyclosome (APC/C), to 
be degraded by ubiquitin ligase complexes. (Moshe et al., 2004a) However, the exact 
role of PLK1 over-expression in the tumorigenesis of HCC or other cancers is still 
uncertain since the physiological role of PLK1 is still not fully defined.  
 
Nuclear fragmentation was detected in Huh-7 when PLK1 gene expression was 
silenced, indicating apoptosis was present. Intriguingly, caspases activation was found 
to be unnecessary in executing apoptosis. The apoptotic effector was identified to be 
endoG, which is a DNase resides exclusively in the mitochondria. EndoG is released 
from mitochondria and translocates to nucleus to cleave DNA independently of 
caspases upon apoptosis induction. (Li et al., 2001) AIF is another effector identified 
in caspase-independent apoptosis pathway (Cregan et al., 2004) but was absent in this 
particular apoptosis pathway. Nevertheless, the presence of both endoG and AIF is 
probably not required to induce apoptosis independently of caspases as showed in 
galectin-1 induced T-cell apoptosis, which is revealed to be independent of caspases, 
AIF, and cytochrome c with only endoG detected. (Hahn et al., 2004) The induction 
of apoptosis that is independent of caspases by silencing PLK1 gene expression in 
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Huh-7 bears significant impact in the treatment of HCC. It is reported that caspase-1 
and caspase-3 expressions are down-regulated in HCC and this could contribute to the 
lack of efficiency in chemotherapy. (Fujikawa et al., 2000) Hence, silencing PLK1 
expression could be useful in achieving more effective treatment for HCC patients; 
probably in combination with current HCC drugs to enhance drug sensitivity as being 
explored in breast cancer recently. (Spankuch et al., 2007)   
 
Examination into the full-length gene sequences of PLK1, including 1 kilo base-pairs 
upstream of the start codon, of HCC patients that had either higher or lower PLK1 
gene expressions revealed no significant mutations. Therefore, overexpression of 
PLK1 might not cause by gain-of-function mutations but depends on the actions of 
other proteins that could regulate PLK1 expression. For instance, Forkhead 
transcription factors (FKH-TF) could bind to PLK1 promoter region in vivo, which 
contains a few FKH-TF binding consensus sites. (Alvarez et al., 2001) One of the 
members of the FKH-TF family, FOXM1 up-regulates PLK1 expression during G2 
phase of the cell cycle. (Laoukili et al., 2005) Coincidently, FOXM1 is associated 
with many cancers (Laoukili et al., 2007) including HCC as showed in this study. 
Gene expressions of FOXM1 and PLK1 were statistically correlated in this study but 
silencing of FOXM1 in Huh-7 had no apparent effects on the gene expression of 
PLK1 as well as in cell proliferation. This result suggests that there might be other 
transcription factors that regulate PLK1 gene expression in addition to FOXM1. 
Indeed, transcription factor E2F1 is recently identified to up-regulates PLK1, PLK3 
and PLK4 gene expressions during cell cycle. (Tategu et al., 2008) Computer-based 
search for binding sites of transcription factors in the PLK1 promoter region also 
suggested putative candidates e.g., NF-Y/CBF, NFĸB and SP1. (Martin and 
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Strebhardt, 2006) Therefore, over-expression of PLK1 in HCC or in other cancers 
could be caused by the actions of multiple transcription factors in a compensatory or 
synergistic way; probably via different deregulated signaling pathways that promote 
oncogenesis. This also implies that PLK1 could be the downstream effector for other 
oncogenes, most notably transcription factors in promoting deregulated cell 
proliferation. This could explain the reason for the increasing number of cancers that 
were found to over-express PLK1.    
 
The results of this study suggest that targeting PLK1 in HCC treatment could be an 
option that is worth exploring. In addition, normal diploid cell lines i.e., hTERT-RPE1 
and MCF10A survive similar PLK1 depletion that otherwise causes mitotic arrest and 
apoptosis in cancer cell lines. (Liu et al., 2006) Normal diploid cells still require 
PLK1 for survival but at a much lower PLK1 level as compared to cancer cells. (Lei 
and Erikson, 2008) Therefore, clinical side effects on HCC patients could be 
minimized by controlling the extent of PLK1 depletion. A novel small molecular 
inhibitor known as BI2536 that inhibits PLK1 protein’s enzymatic activity with high 
selectivity and potency has been introduced. (Lenart et al., 2007; Steegmaier et al., 
2007b) This drug has been evaluated in phase I clinical trials in patients with 
advanced solid tumor with reported anti-tumor activity and neutropenia as 
dose-limiting toxicity. (Mross et al., 2005a) Phase II clinical trials of BI2536 are 
currently ongoing with various tumor indications. (Schmidt and Bastians, 2007) Such 
inhibitor could probably be suitable in treating HCC or used in combination with 
other drugs to better HCC treatment outcomes.    
 
In conclusion, PLK1 is over-expressed in HCC and the gene silencing experiments 
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showed significant anti-proliferative effect in human HCC cell line Huh-7 in vitro and 
in vivo. Induction of casapse-independent apoptosis pathway by silencing PLK1 could 
probably improve the sensitivity of chemotherapy in HCC patients. Hence, PLK1 is a 
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Table 1: Relative Gene Expressions of the Selected Target Genes in 56 Hepatocellular 






Percentage of Patients 
that Had Up-regulation 




Polo-like kinase 1 12.74 95% (53) 0.000 
FOXM1 
Forkhead box M1 5.36 93% (52) 0.000 
PTTG1 
Pituitary 
tumor-transforming gene 1 




1.96 80% (45) 0.000 
RCN2 








1.29 64% (36) 0.044 
S100P 
S100 calcium binding 
protein P 
1.69 62% (35) 0.081 
USP5 
Ubiquitin specific 
peptidase 5  
(isopeptidase T) 
1.34 62% (35) 0.081 
XBP1 
X-box binding protein 1 1.08 52% (29) 0.894 
 
Gene expression in every HCC tissues was quantified relative to the corresponding 
non-tumor tissues using 2-∆∆Ct method by real-time RT-PCR. 
P-value is determined by Binomial test with dichotomy cut point set at 1 (indicates no 
difference in relative gene expression).
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Table 2: The Correlations between Polo-like Kinase 1 (PLK1) Relative Gene 
Expression and Clinicopathological Parameters in 56 Hepatocellular Carcinoma 
(HCC) Patients. 
 
Clinicopathological Parameter n 
Relative Gene 
Expression 
(Mean ± SEM) 
P- value 
Age    
     <65 years 42 18.35 ± 2.95 0.570† 
     ≥65 years 14 16.15 ± 5.11  
Gender    
     Male 49 17.24 ± 2.74 0.436† 
     Female 7 21.72 ± 6.83  
Histological type of tumor    
     Well differentiated 2 14.00 ± 13.10 0.846‡ 
     Moderately differentiated 41 17.39 ± 2.92  
     Poorly differentiated 13 19.69 ± 5.87  
Liver cirrhosis    
     Present 44 16.05 ± 2.42 0.497† 
     Absent 12 24.22 ± 7.83  
Pathological stage    
     I 1 5.68 0.849‡ 
     II 5 14.11 ± 6.67  
     III 32 17.68 ± 2.93  
     IV 18 19.72 ± 5.74  
 
PLK1 gene expression in every HCC tissues was quantified relative to the 
corresponding non-tumor tissues using 2-∆∆Ct method by real-time RT-PCR. 
P-value was determined by † Mann-Whitney test and ‡ Kruskal-Wallis test. 
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Table 3: Polo-like Kinase 1 (PLK1) Relative Gene Expressions in Normal Human 
Liver Tissues and Human Hepatoma Cell Lines. 
 
Origin Relative Gene Expression (Mean ± SEM) 
Normal human adult liver 0.007±0.002 





PLK1 gene expression was quantified relative to Human total RNA reference control 
using 2-∆∆Ct method by real-time RT-PCR. 
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Figure 1: MTS assay measures the metabolic activity of living cells. (A) Huh-7 was transfected respectively with non-targeting siRNA pool, 
si-NT (  ), siRNA against PLK1, si-PLK1 (  ), transfection reagent only (  ), or without transfection (  ). Figure shows a 
representative result from three independent experiments in triplicate. (B) The percentage of reduction in absorbance across increasing si-PLK1 
concentrations from three independent experiments. All data was represented in mean ± SEM. Student’s T-test was used for comparisons 
between data sets (** p < 0.05). 
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Figure 2: BrdU assay measures DNA replication in replicating cells. (A) Huh7 was transfected respectively with non-targeting siRNA pool, 
si-NT (  ), siRNA against PLK1, si-PLK1 (  ), transfection reagent only (  ), or without transfection (  ). Figure shows a 
representative result from three independent experiments in triplicate. (B) The percentage of reduction in rlu/s across increasing si-PLK1 
concentrations from three independent experiments. All data was represented in mean ± SEM. Student’s T-test was used for comparisons 
































































































Figure 3: PLK1 gene expression was successfully silenced by siRNA. (A) Huh-7 was transfected respectively with non-targeting siRNA pool, 
si-NT (  ), siRNA against PLK1, si-PLK1 (  ), transfection reagent only (  ), or without transfection (  ). Figure shows a 
representative result from three independent experiments in triplicate. (B) The percentage of reduction in gene expression across increasing 
si-PLK1 concentrations from three independent experiments. All data was represented in mean ± SEM. Student’s T-test was used for 
comparisons between data sets (** p < 0.05). PLK1 gene expression was quantified relative to Human total RNA reference control using 2-∆∆Ct 
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Figure 4: Silencing of PLK1 gene expression by si-PLK1 was translated into 
corresponding reduction in PLK1 protein expression in Huh-7. The si-PLK1 and 
si-NT concentrations used were 50 nM. Figure shows a representative result from 

















Figure 5: Confocal fluorescence images of Huh-7 cells. α-tubulins were stained with FITC (green) 
and nuclei were counterstained with DAPI (blue). si-PLK1 (50 nM) transfected Huh-7 cells (left) 
appeared to be binucleated and the spindle assembly was absent. si-NT (50nM) transfected Huh-7 
cells (right) were completing mitosis instead with functional spindle assembly. Huh-7 cells were 
processed for confocal imaging after 24 hours of transfections. si-PLK1, siRNA against PLK1; 
































Figure 6: Silencing of PLK1 gene expression induced apoptosis in Huh-7. (A) 
Nuclear fragmentation is expressed as enrichment factor, which is a ratio of the 
sample’s absorbance to absorbance of the no-transfection control. Enrichment factor 
greater than 1 indicates enrichment of mono- and oligonucleosomes in the cytoplasm 
of the apoptotic cells due to DNA fragmentation. Huh-7 was transfected respectively 
with non-targeting siRNA pool, si-NT (  ), siRNA against PLK1, si-PLK1 (  ), 
transfection reagent only (  ), or without transfection. Huh-7 treated with 5 μM 
thapsigargin, a drug that is reported to induce apoptosis in Huh-7 (Xie et al., 2002), 
was used as positive control (  ). Figure shows a representative result from three 
independent experiments in triplicate. All data was represented in mean ± SEM. 
Student’s T-test was used for comparisons between data sets (** p < 0.05).  




Figure 7: TUNEL fluorescence images. Fragmented DNA is labeled with fluorescein-12-dUTP by terminal deoxynucleotidyl transferase as 
illustrated in the image on the left. An apoptotic Huh-7 cell is marked by block arrowhead while a non-apoptotic Huh-7 cell is marked by hollow 
arrowhead. Both cells are also marked respectively in DAPI counterstained image on the right. It could be observed clearly that the TUNEL 
staining was colocalized to the fragmented chromosomes in apoptotic cell. Non-apoptotic cell was not labeled by TUNEL and its chromosomes 






















Figure 8: Caspase 3 activity was measured using a fluorometric immunosorbent 
enzyme assay with cell lysates from two millions Huh-7 cells that were transfected 
respectively with non-targeting siRNA pool, si-NT (  ), 50 nM siRNA against 
PLK1, si-PLK1 (  ), transfection reagent only (  ), or without transfection (  ). 
Positive control (  ), which is the cell lysates from U937 cells treated with 
camptothecin, is supplied with the kit. No apparent caspase 3 activity was detected in 
si-PLK1 transfected Huh-7 after 12 hours and 24 hours of transfection. Figure shows 
a representative result from three independent experiments in triplicate. All data was 
represented in mean ± SEM. Student’s T-test was used for comparisons between data 




























Figure 9: Apoptosis induced by silencing PLK1 gene expression in Huh-7 did not 
require caspases. (A) MTS cell proliferation assay was performed on Huh-7 that was 
transfected respectively with non-targeting siRNA pool, si-NT (  ), and siRNA 
against PLK1, si-PLK1 (  ), in the presence of the pan caspase inhibitor, 
Z-VAD-FMK. The pan caspase inhibitor failed to protect Huh-7 transfected with 
si-PLK1 from apoptosis. In contrary, HepG2 that were treated with camptothecin and 
Z-VAD-FMK (  ) was protected from apoptosis induced by camptothecin while the 
one that was treated with camptothecin without Z-VAD-FMK (  ) was not 
protected from apoptosis. Figure shows a representative result from three independent 
experiments in triplicate. All data was represented in mean ± SEM. Student’s T-test 






















Figure 10: Caspase-independent apoptosis. Huh-7 transfected with 50 nM siRNA against PLK1 for 24 
hours was probed with antibody against endonuclease G or apoptosis-inducing factor and subsequently 
visualized with FITC-conjugated secondary antibody (Left panel). The corresponding DAPI 
counterstained images are showed in the right panel. Block arrowheads and hollow arrowheads mark 
apoptotic and non-apoptotic Huh-7 cells respectively. Endonuclease G was positively stained in 
apoptotic cells and showed colocalization to the fragmented chromosomes while peripheral staining 
was showed in non-apoptotic cells indicating endonuclease G was localized in mitochondrial. 









Figure 11: Scatter plot of PLK1 and FOXM1 gene expressions from 56 
Hepatocellular carcinoma (HCC) patients shows significant positive correlations (p < 
0.05) in both non-parametric correlation tests: Kendall’s tau and Spearman’s rho 
(Respective correlation coefficients are indicated). Gene expression in every HCC 
tissues was quantified relative to the corresponding non-tumor tissues using 2-∆∆Ct 
method by real-time RT-PCR.
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Figure 12: Silencing of FOXM1 gene expression did not affect the gene expression of PLK1. (A) Although FOXM1 gene expression was 
successfully silenced as showed in the left side of the histogram, PLK1 gene expression was not affected at all (right side). Huh-7 were 
transfected respectively with 50 nM non-targeting siRNA pool, si-NT (  ), or 50 nM siRNA against FOXM1, si-FOXM1 (  ). PLK1 gene 
expression was quantified relative to Human total RNA reference control using 2-∆∆Ct method by real-time RT-PCR. (B) MTS cell proliferation 
assay showed no significant reductions in cell proliferations across increasing concentrations of si-FOXM1. Huh-7 was transfected respectively 
with si-NT (  ), si-FOXM1 (  ), transfection reagent only (  ), or without transfection (  ). Figures show representative results from 
three independent experiments in triplicate. All data was represented in mean ± SEM. Student’s T-test was used for comparisons between data 













Figure 13: Treatment of si-PLK1 in nude mice impeded the tumor growth. (A) Huh-7 
tumor-bearing nude mice were treated with 1 nmol si-PLK1 through intratumor 
injections every alternate day for 27 days. All data was represented in mean ± SEM. 
Student’s T-test was used for comparisons between data sets (** p < 0.05). (B) Images 






Adams RR, Tavares AA, Salzberg A, Bellen HJ, Glover DM (1998). pavarotti encodes 
a kinesin-like protein required to organize the central spindle and contractile ring for 
cytokinesis. Genes Dev 12: 1483-1494. 
 
Ahonen LJ, Kallio MJ, Daum JR, Bolton M, Manke IA, Yaffe MB et al (2005). 
Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates 
the association of spindle-checkpoint proteins at kinetochores. Curr Biol. 15: 
1078-1089. 
 
Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U et al (2002). 
Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 
359: 131-2. 
 
Alexandru G, Uhlmann F, Mechtler K, Poupart MA, Nasmyth K (2001). 
Phosphorylation of the cohesin subunit Scc1 by Polo/Cdc5 kinase regulates sister 
chromatid separation in yeast. Cell 105: 459-472. 
 
Alvarez B, Martinez AC, Burgering BM, Carrera AC (2001). Forkhead transcription 
factors contribute to execution of the mitotic programme in mammals. Nature 413: 
744-7. 
 
Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al (2004). 
  41
Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and 
phosphorylation. J Biol Chem 279: 25549-25561. 
 
Arnaud L, Pines J, Nigg EA (1998). GFP tagging reveals human Polo-like kinase 1 at 
the kinetochore/centromere region of mitotic chromosomes. Chromosoma 107: 
424-429. 
 
Aumais JP, Williams SN, Luo W, Nishino M, Caldwell KA, Caldwell GA et al (2003). 
Role for NudC, a dynein-associated nuclear movement protein, in mitosis and 
cytokinesis. J Cell Sci 116: 1991-2003. 
 
Avila MA, Berasain C, Sangro B, Prieto J (2006). New therapies for hepatocellular 
carcinoma. Oncogene 25: 3866-84. 
 
Bahassi el M, Hennigan RF, Myer D, Stambrook PJ (2004). Cdc25C phosphorylation 
on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 23: 2658-2663. 
 
Barr FA, Silljé HHW, Nigg EA (2004). Polo-like kinases and the orchestration of cell 
division. Mol Cell Biol 5: 429-440. 
 
Baumann C, Korner R, Hofmann K, Nigg EA (2007). PICH, a centromere-associated 
SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. 
Cell 128: 101-14. 
 
Beerheide W, Tan YJ, Teng E, Ting AE, Jedpiyawongse A, Srivatanakul P (2000). 
  42
Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing 
hepatocellular carcinomas. Biochem Biophys Res Commun 273: 54-61. 
 
Bharadwaj R, Yu H (2004). The spindle checkpoint, aneuploidy, and cancer. 
Oncogene 23: 2016-2027. 
 
Bruix J, Llovet J (2002). Prognostic prediction and treatment strategy in 
hepatocellular carcinoma. Hepatology 35: 519-24. 
 
Bruix J, Sherman M (2005). Management of hepatocellular carcinoma. Hepatology 42: 
1208-36. 
 
Bu Y, Yang Z, Li Q, Song F (2008). Silencing of polo-like kinase (Plk) 1 via siRNA 
causes inhibition of growth and induction of apoptosis in human esophageal cancer 
cells. Oncology 74: 198-206. 
 
Budde PP, Kumagai A, Dunphy WG, Heald R (2001). Regulation of Op18 during 
spindle assembly in Xenopus egg extracts. J Cell Bio 153: 149-158. 
 
Carnero A (2002). Targeting the cell cycle for cancer therapy. British Journal of 
Cancer. 87: 129-133. 
 
Casenghi M, Meraldi P, Weinhart U, Duncan PI, Korner R, Nigg EA (2003). Polo-like 
kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev 
Cell 5: 113-125. 
  43
 
Chase D, Golden A, Heidecker G, Ferris DK (2000). Caenorhabditis elegans contains 
a third polo-like kinase gene. DNA Seq. 11: 327-34. 
 
Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J et al (2002). Gene expression 
patterns in human liver cancers. Mol Biol Cell 13: 1929-39. 
 
Chen XH, Lan B, Qu Y, Zhang XQ, Cai Q, Liu BY et al (2006a). Inhibitory effect of 
Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J 
Gastroenterol 12: 29-35. 
 
Chen XH, Lan B, Qu Y, Zhang XQ, Cai Q, Liu BY et al (2006b). Inhibitory effect of 
Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J 
Gastroenterol 12: 29-35. 
 
Chen XJ, Wu LM, Xu XB, Feng XW, Xie HY, Zhang M et al (2007). [Expression and 
prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular 
carcinoma]. Zhonghua Wai Ke Za Zhi 45: 1354-8. 
 
Clay F, McEwen S, Bertoncello I, Wilks A, Dunn A (1993). Identification and cloning 
of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. 
Proc Nat Acad Sci 90: 4882-86. 
 
Cleveland DW, Mao Y, Sullivan KF (2003). Centromeres and kinetochores: from 
epigenetics to mitotic checkpoint signaling. Cell 112: 407-421. 
  44
 
Cregan SP, Dawson VL, Slack RS (2004). Role of AIF in caspase-dependent and 
caspase-independent cell death. Oncogene 23: 2785-96. 
 
de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T et al (2005). 
Normalization of gene expression measurements in tumor tissues: comparison of 13 
endogenous control genes. Lab Invest 85: 154-9. 
 
Dietzmann K, Kirches E, von Bossanyi P, Jachau K, Mawrin C (2001). Increased 
human polo-like kinase-1 expression in gliomas. J. Neurooncol. 53: 1-11. 
 
do Carmo Avides M, Tavares A, Glover DM (2001). Polo kinase and Asp are needed 
to promote the mitotic organizing activity of centrosomes. Nature Cell Bio 3: 
421-424. 
 
Duncan PI, Pollet N, Niehrs C, Nigg EA (2001). Cloning and characterization of Plx2 
and Plx3, two additional Polo-like kinases from Xenopus laevis. Exp. Cell Res. 270: 
78-87. 
 
Eckerdt F, Strebhardt K (2006). Polo-like kianse 1: Target and regulator of 
anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res. 66: 
6895-6898. 
 




El-Serag H, Rudolph K (2007). Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology 132: 2557-76. 
 
Elia AE, Cantley LC, Yaffe MB (2003a). Proteomic screen finds pSer/pThr-binding 
domain localizing Plk1 to mitotic substrates. Science 299: 1228-1231. 
 
Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K et al (2003b). The 
molecular basis for phosphodependent substrate targeting and regulation of Plks by 
the Polo-box domain. Cell 115: 83-95. 
 
Elledge SJ (1996). Cell cycle checkpoints: preventing an identity crisis. Science 274: 
1664-1672. 
 
Ferlay J, Bray F, Pisani P, Parkin DM (2004). GLOBOCAN 2002: Cancer Incidence, 
Mortality and Prevalence Worldwide. IARCPress: Lyon. 
 
Fode C, Motro B, Yousefi S, Heffernan M, Dennis JW (1994). Sak, a murine 
protein-serine/threonine kinase that is related to the Drosophila polo kinase and 
involved in cell proliferation. Proc Nat Acad Sci 91: 6388-92. 
 
Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T et al (2006). 
Overexpression of pituitary tumor transforming gene 1 in HCC is associated with 
angiogenesis and poor prognosis. Hepatology 43: 1267-75. 
 
  46
Fujikawa K, Shiraki K, Sugimoto K, Ito T, Yamanaka T, Takase K et al (2000). 
Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular 
carcinoma. Anticancer Res 20: 1927-32. 
 
Glover DM, Hagan IM, Tavares A (1998). Polo-like kinases: a team that plays 
throughout mitosis. Genes Dev. 12: 3777-87. 
 
Golan A, Yudkovsky Y, Hershko A (2002). The cyclin-ubiquitin ligase activity of 
cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J Biol 
Chem 277: 15552-15557. 
 
Golsteyn R, Schultz S, Bartek J, Ziemiecki A, Ried T, Nigg E (1994). Cell cycle 
analysis and chromosomal localization of human Plk1, a putative homologue of the 
mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 107: 
1509-1517. 
 
Gray PJ, Jr, Bearss DJ, Han H, Nagle R, Tsao M-S, Dean N et al (2004). Identification 
of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol 
Cancer Ther. 3: 641-6. 
 
Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y (2005). Small 
Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the 
Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth 
in Animals. Cancer Res. 65: 2698-704. 
 
  47
Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al 
(2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a 
potent anticancer agent. Cancer Cell. 7: 275-86. 
 
Hahn HP, Pang M, He J, Hernandez JD, Yang RY, Li LY et al (2004). Galectin-1 
induces nuclear translocation of endonuclease G in caspase- and cytochrome 
c-independent T cell death. Cell Death Differ 11: 1277-86. 
 
Hamanaka R, Maloid S, Smith M, O'Connell C, Longo D, Ferris DK (1994). Cloning 
and characterization of human and murine homologues of the Drosophila polo 
serine-threonine kinase. Cell Growth Differ 5: 249-257. 
 
Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K (1995). The 
clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. 
Hepatology 22: 1702-7. 
 
Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda1 C et al (2004). Polo-like 
kinase 1 overexpression is an early event in the progression of papillary carcinoma. 
British Journal of Cancer 90: 414-8. 
 
Jackman M, Lindon C, Nigg EA, Pines J (2003). Active cyclin B1-Cdk1 first appears 
on centrosomes in prophase. Nat Cell Biol 5: 143-148. 
 
Jang Y, Kim Y, Kim W (2006). Oncogenic effect of Polo-like kinase 1 expression in 
human gastric carcinomas. Int J Oncol. 29: 589-94. 
  48
 
Jang YJ, Lin CY, Ma S, Erikson RL (2002a). Functional studies on the role of the 
C-terminal domain of mammalian polo-like kinase. Proc Nat Acad Sci 99: 1984-1989. 
 
Jang YJ, Ma S, Terada Y, Erikson RL (2002b). Phosphorylation of threonine 210 and 
the role of serine 137 in the regulation of mammalian polo-like kinase. J Biol Chem 
277: 44115-44120. 
 
Johnson LN, Noble MEM, Owen DJ (1996). Active and inactive protein kinases: 
structural basis for regulation. . Cell 85: 149-158. 
 
Karn T, Holtrich U, Wolf G, Hock B, Strebhardt K, Rubsamen-Waigmann H (1997). 
Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA 
expression in testis. Oncol. Reports 4: 505-10. 
 
Kitada K, Johnson AL, Johnston LH, Sugino A (1993). A multicopy suppressor gene 
of the Saccharomyces cerevisiae G1 cell cycle mutant gene dbf4 encodes a protein 
kinase and is identified as CDC5. Mol Cell Biol 13: 4445-57. 
 
Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K (1999). 
Prognostic significance of polo-like kinase (PLK) expression in squamous cell 
carcinomas of the head and neck. Cancer Res. 59: 2794-7. 
 
Knecht R, Oberhauser C, Strebhardt K (2000). PLK (polo-like kinase), a new 
prognostic marker for oropharyngeal carcinomas. Int J Cancer. 89: 535-6. 
  49
 
Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R (2002). 
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of 
metastatic disease. Cutan Pathol. 29: 354-8. 
 
Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS et al 
(1991a). Crystal structure of the catalytic subunit of cyclic adenosine 
monophosphate-dependent protein kinase. Science 253: 407-414. 
 
Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM (1991b). 
Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine 
monophosphate-dependent protein kinase. Science 253: 414-420. 
 
Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C et al (1998). 
PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex 
activity and mitosis progression. Mol Cell. 1: 371-380. 
 
Kothe M, Kohls D, Low S, Coli R, Cheng AC, Jacques SL et al (2007). Structure of 
the catalytic domain of human polo-like kinase 1. Biochemistry 46: 5960-5971. 
 
Kumagai A, Dunphy W (1996). Purification and molecular cloning of Plx1, a 
Cdc25-regulatory kinase from Xenopus egg extracts. Science 273: 1377-80. 
 
Lake RJ, Jelinek WR (1993). Cell-cycle and terminal differentiation-associated 
regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell 
  50
Biol 13: 7793-801. 
 
Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A et al (2005). 
FoxM1 is required for execution of the mitotic programme and chromosome stability. 
Nat Cell Biol 7: 126-36. 
 
Laoukili J, Stahl M, Medema RH (2007). FoxM1: at the crossroads of ageing and 
cancer. Biochim Biophys Acta 1775: 92-102. 
 
Lee BH, Amon A (2003). Role of Polo-like kinase CDC5 in programming meiosis I 
chromosome segregation. Science 300: 482-486. 
 
Lee J, Chu I, Heo J, Calvisi D, Sun Z, Roskams T et al (2004). Classification and 
prediction of survival in hepatocellular carcinoma by gene expression profiling. 
Hepatology 40: 667-76. 
 
Lee KS, Erikson RL (1997). Plk is a functional homolog of Saccharomyces cerevisiae 
Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol 17: 
3408-17. 
 
Lee KS, Yuan Y-L, Kuriyama R, Erikson RL (1995). Plk is an M-phase-specific 
protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell 
Biol 15: 7143-7151. 
 
Lei M, Erikson RL (2008). Plk1 depletion in nontransformed diploid cells activates 
  51
the DNA-damage checkpoint. Oncogene. 
 
Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M et al (2007). 
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of 
polo-like kinase 1. Curr Biol 17: 304-15. 
 
Leung GC, Hudson JW, Kozarova A, Davidson A, Dennis JW, Sicheri F (2002). The 
Sak polo-box comprises a structural domain sufficient for mitotic subcellular 
localization. Nature Structural Biology 9: 719-724. 
 
Levine A (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 
323-331. 
 
Li B, Ouyang B, Pan H, Reissmann P, Slamon D, Arceci R et al (1996). prk, a 
cytokine-inducible human protein serine/threonine kinase whose expression appears 
to be down-regulated in lung carcinomas. J Biol Chem 271: 19402-19408. 
 
Li LY, Luo X, Wang X (2001). Endonuclease G is an apoptotic DNase when released 
from mitochondria. Nature 412: 95-9. 
 
Litvak V, Argov R, Dahan N, Ramachandran S, Amarilio R, Shainskaya A et al (2004). 
Mitotic phosphorylation of the peripheral Golgi protein Nir2 by Cdk1 provides a 




Liu L, Zhang M, Zou P (2007). Expression of PLK1 and survivin in diffuse large 
B-cell lymphoma. Leukemia and Lymphoma 48: 2179-83. 
 
Liu X, Erikson RL (2002). Activation of Cdc2/cyclin B and inhibition of centrosome 
amplification in cells depleted of Plk1 by siRNA. Proc Nat Acad Sci 99. 
 
Liu X, Erikson RL (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in 
cancer cells. Proc Nat Acad Sci 100: 5789-94. 
 
Liu X, Lei M, Erikson RL (2006). Normal cells, but not cancer cells, survive severe 
Plk1 depletion. Mol. Cell. Biol. 26: 2093-108. 
 
Llamazares S, Moreira A, Tavares A, Girdham C, Spruce B A, Gonzalez C et al 
(1991). polo encodes a protein kinase homolog required for mitosis in Drosophila. 
Genes Dev. 5: 2153-65. 
 
Llovet J, Fuster J, Bruix J (1999). Intention-to-treat analysis of surgical treatment for 
early hepatocellular carcinoma:resection versus transplantation. Hepatology 39: 
1434-40. 
 
Losada A, Hirano M, Hirano T (2002). Cohesin release is required for sister 
chromatid resolution, but not for condensin-mediated compaction, at the onset of 
mitosis. Genes Dev. 16: 3004-3016. 
 
Lowery DM, Lim D, Yaffe MB (2005). Structure and function of Polo-like kinases. 
  53
Oncogene 24: 248-59. 
 
Macmillan JC, Hudson JW, Bull S, Dennis JW, Swallow CJ (2001). Comparative 
Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer. Annals of 
Surgical Oncology 8: 729-40. 
 
Martin BT, Strebhardt K (2006). Polo-like kinase 1: target and regulator of 
transcriptional control. Cell Cycle 5: 2881-5. 
 
Matsumura S, Toyoshima F, Nishida E (2007). Polo-like kinase 1 facilitates 
chromosome alignment during prometaphase through BubR1. J Biol Chem 282: 
15217-15227. 
 
Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S (2005). Expression 
of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. Leukemia and Lymphoma 
46: 225-31. 
 
Moshe Y, Boulaire J, Pagano M, Hershko A (2004a). Role of Polo-like kinase in the 
degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting 
complex/cyclosome. Proc Natl Acad Sci U S A 101: 7937-42. 
 
Moshe Y, Boulaire J, Pagano M, Hershko A (2004b). Role of Polo-like kinase in the 
degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting 
complex/cyclosome. Proc Nat Acad Sci 101. 
 
  54
Mross K, Steinbild S, Frost A, Hedborn S, Rentschler J, Kaiser R et al (2005a). A 
Phase I single dose escalation study of the Polo-like kinase 1 (Plk1) inhibitor BI 2536 
in patients with advanced solid tumors. Clin. Cancer Res.Suppl. 11: 9032. 
 
Mross K, Steinbild S, Frost A, Hedborn S, Rentschler J, Kaiser R et al (2005b). A 
Phase I single dose escalation study of the Polo-like kinase 1 (Plk1) inhibitor BI 2536 
in patients with advanced solid tumors. Clin. Cancer Res. 11: 9032. 
 
Mundt KE, Golsteyn RM, Lane HA, Nigg EA (1997). On the regulation and function 
of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle 
progression. Biochem Biophys Res Commun 239: 377-385. 
 
Musacchio A, Hardwick K (2002). The spindle checkpoint: structural insights into 
dynamic signalling. Nat Rev Mol Cell Biol 3. 
 
Neef R, Gruneberg U, Kopajtich R, Li X, Nigg EA, Sillje H et al (2007). Choice of 
Plk1 docking partners during mitosis and cytokinesis is controlled by the activation 
state of Cdk1. Nat Cell Biol 9: 436-444. 
 
Neef R, Preisinger C, Sutcliffe J, Kopajtich R, Nigg EA, Mayer TU et al (2003). 
Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for 
cytokinesis. J Cell Biol 162: 863-875. 
 
Nigg E (1998). Polo-like kinases: positive regulators of cell division from start to 
finish. Cell Biol. 10: 776-83. 
  55
 
Nigg EA (2001). Mitotic kinases as regulators of cell division and its checkpoints. 
Nature Rev Mol Cell Biol 2: 21-32. 
 
Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K (2007). BUB1 mediation of 
caspase-independent mitotic death determines cell fate. J Cell Biol 178: 283-96. 
 
Nishino M, Kurasawa Y, Evans R, Lin S, Brinkley B, Yu-Lee L (2006). NudC is 
required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol. 
16: 1414-1421. 
 
Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K et al (2005). Intravesical 
administration of small interfering RNA targeting PLK-1 successfully prevents the 
growth of bladder cancer. J. Clin. Invest. 115: 978-85. 
 
Ohkura H, Hagan IM, Glover DM (1995). The conserved Shizosaccharomyces pombe 
kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive 
septum formation in G1 and G2 cells. Genes & Dev 9: 1059-73. 
 
Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al (2001). 
Genome-wide analysis of gene expression in human hepatocellular carcinomas using 
cDNA microarray: identification of genes involved in viral carcinogenesis and tumor 
progression. Cancer Res 61: 2129-37. 
 
Osada S, Saji S, Kuno T (2004). Clinical significance of combination study of 
  56
apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of 
hepatocellular carcinoma. J Surg Oncol 85: 48-54. 
 
Ouyang B, Pan H, Dagger LL, Li J, Stambrook P, Li B et al (1997). Human Prk Is a 
Conserved Protein Serine/Threonine Kinase Involved in Regulating M Phase 
Functions. J Biol Chem 272: 28646-51. 
 
Ouyang B, Wang Y, Dai W (1999). Caenorhabditis elegans contains structural 
homologs of human prk and plk. DNA Seq. 10: 109-13. 
 
Pang R, Tse E, Poon RT (2006). Molecular pathways in hepatocellular carcinoma. 
Cancer Lett 240: 157-69. 
 
Peters JM (2002). The anaphase-promoting complex: proteolysis in mitosis and 
beyond. Mol Cell Biol 9: 931-943. 
 
Qian YW, Erikson E, Maller JL (1999). Mitotic effects of a constitutively active 
mutant of the Xenopus polo-like kinase Plx1. Mol. Cell. Biol. 19: 8625-8632. 
 
Reagan-Shaw S, Ahmad N (2005). Silencing of polo-like kinase (Plk) 1 via siRNA 
causes induction of apoptosis and impairment of mitosis machinery in human prostate 
cancer cells: implications for the treatment of prostate cancer. FASEB J 19: 611-3. 
 
Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA (2000). The 
human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and 
  57
activation of the cdc25C phosphatase. Cell Signal. 12: 405-411. 
 
Schmidt M, Bastians H (2007). Mitotic drug targets and the development of novel 
anti-mitotic anticancer drugs. Drug Resist Updat 10: 162-81. 
 
Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T et al (2002). A 
spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box 
domain of Plk1 in U-2 OS cells. J Biol Chem 277: 32282-32293. 
 
Shaw SR, Ahmad N (2005). Silencing of polo-like kinase (Plk) 1 via siRNA causes 
induction of apoptosis and impairment of mitosis machinery in human prostate cancer 
cells: implications for the treatment of prostate cancer. FASEB 19: 611-3. 
 
Simmons DL, Neel BG, Stevens R, Evett G, Erikson RL (1992). Identification of an 
early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol. 
12: 4164-69. 
 
Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL et al (1997). 
Malignant transformation of mammalian cells initiated by constitutive expression of 
the polo-like kinase. Biochem Biophys Res Commun. 234: 397-405. 
 
Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH (2000). 




Soini Y, Virkajarvi N, Lehto VP, Paakko P (1996). Hepatocellular carcinomas with a 
high proliferation index and a low degree of apoptosis and necrosis are associated 
with a shortened survival. Br J Cancer 73: 1025-30. 
 
Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002). Effect of 
RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in 
human cancer cells. J Natl Cancer Inst 94: 1863-77. 
 
Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K (2007). Rational 
combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26: 
5793-807. 
 
Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K (2007). Rational 
combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26: 
5793-807. 
 
Spänkuch SB, Bereiter HJ, Kaufmann M, Strebhardt K (2002). Effect of RNA 
silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human 
cancer cells. J Natl Cancer Inst. 94: 1863-77. 
 
Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M et al 
(2007a). BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), 




Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al 
(2007b). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor 
growth in vivo. Curr Biol 17: 316-22. 
 
Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R (2000). Prognostic value of 
polo like kinase expression in melanomas. JAMA 283: 479-80. 
 
Su MC, Hsu HC, Liu YJ, Jeng YM (2006). Overexpression of pituitary 
tumor-transforming gene-1 in hepatocellular carcinoma. Hepatogastroenterology 53: 
262-5. 
 
Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S (1999). The significance of p53 
mutations as an indicator of the biological behavior of recurrent hepatocellular 
carcinomas. Surg Today 29: 849-55. 
 
Sunkel CE, Glover DM (1988). polo, a mitotic mutant of Drosophila displaying 
abnormal spindle poles. J Cell Sci. 89: 25-38. 
 
Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K et al (2003). 
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 
94: 148-52. 
 
Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I (2005). Polo-like kinases (Plks) and 
cancer. Oncogene 24: 287-91. 
 
  60
Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I (2001a). 
Expression of polo-like kinase in ovarian cancer is associated with histological grade 
and clinical stage. Cancer Lett. 164: 41-9. 
 
Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I (2001b). 
Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 169: 41-9. 
 
Tategu M, Nakagawa H, Sasaki K, Yamauchi R, Sekimachi S, Suita Y et al (2008). 
Transcriptional regulation of human polo-like kinases and early mitotic inhibitor. J 
Genet Genomics 35: 215-24. 
 
Thorgeirsson SS, Grisham JW (2002). Molecular pathogenesis of human 
hepatocellular carcinoma. Nat Genet 31: 339-46. 
 
Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y (1999). Prognostic 
significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol. 15: 
687-92. 
 
Toyoshima-Morimoto F, Taniguchi E, Nishida E (2002). Plk1 promotes nuclear 
translocation of human Cdc25C during prophase. EMBO Rep 3: 341-348. 
 
Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E (2001). 
Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during 
prophase. Nature 410: 215-220. 
 
  61
van Vugt MA, Smits VA, Klompmaker R, Medema RH (2001). Inhibition of Polo-like 
kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 
276: 41656-41660. 
 
van Vugt MA, Van De Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R et al 
(2004). Polo-like kinase-1 is required for bipolar spindle formation but is dispensable 
for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol 
Chem 279: 36841-36854. 
 
Vogelstein B, Kinzler KW (1993). The multistep nature of cancer. Trends Genet. 9: 
138-141. 
 
Warren RS, Kirn DH (2002). Liver-directed viral therapy for cancer p53-targeted 
adenoviruses and beyond. Surg Oncol Clin N Am 11: 571-88, vi. 
 
Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M et al (2004a). 
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. 
British Journal of Cancer 90: 815-21. 
 
Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S et al 
(2005a). Polo-like kinase 1 expression is a prognostic factor in human colon cancer. 
World J Gastroenterol. 11: 5644-50. 
 
Weichert W, Kristiansen G, Winzer K-J, Schmidt M, Gekeler V, Noske A et al (2005b). 
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic 
  62
implications. Virchows Archiv. 446: 442-50. 
 
Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K et al (2004b). 
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor 
grades. Prostate 60: 240-5. 
 
Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P et al (2005c). 
Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic 
Cancer. Pancreatology. 5: 259-65. 
 
Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ et al (1997). 
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung 
cancer. Oncogene 14: 543-9. 
 
Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ et al (2000). 
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor 
expression in human breast cancer. Pathol Res Pract. 196: 753-9. 
 
Wong OK, Fang G (2005). Plx1 is the 3F3/2 kinase responsible for targeting spindle 
checkpoint proteins to kinetochores. J Cell Biol 170: 709-719. 
 
Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE et al (2002). Effect 
of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 
activation. Hepatology 36: 592-601. 
 
  63
Xie S, Xie B, Lee M, Dai W (2005). Regulation of cell cycle checkpoints by polo-like 
kinases. Oncogene 54: 277-286. 
 
Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC (1996). 
Tissue-specific growth suppression and chemosensitivity promotion in human 
hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 
gene. Hepatology 24: 1264-8. 
 
Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y et al (2004). 
Expression profiling and differential screening between hepatoblastomas and the 
corresponding normal livers: identification of high expression of the PLK1 oncogene 
as a poor-prognostic indicator of hepatoblastomas. Oncogene 23: 5901-11. 
 
Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H et al (1996). 
Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83: 1219-22. 
 
Yarm FR (2002). Plk  phosphorylation regulates the microtubule-stabilizing protein 
TCTP. Mol Cell Biol 22: 6209-6221. 
 
Zhou BB, Elledge SJ (2000). The DNA damage response: putting checkpoints in 
perspective. Nature 408: 433-439. 
 
Zhou T, Aumais JP, Liu X, Yu-Lee LY, Erikson RL (2003). A role for Plk1 
phosphorylation of NudC in cytokinesis. Dev. Cell 5: 127-138. 
 




Table A1: Relative Gene Expression of the Selected Target Genes in 56 Hepatocellular Carcinoma Patients (Complete List)  
 
Relative Gene Expression 
Patient 
PLK1 FOXM1 PTTG1 USP21 RCN2 DUSP12 USP1 S100P USP5 XBP1 
10 1.18 1.18 1.27 0.64 1.08 0.84 0.49 0.15 0.48 0.71 
23 24.17 5.93 11.95 2.33 5.00 1.49 1.08 0.78 2.01 0.73 
27 4.71 2.30 10.15 3.35 1.51 12.57 13.45 6.29 12.08 2.16 
38 5.21 3.41 13.34 0.67 1.80 0.60 0.78 0.86 1.22 0.39 
42 31.21 13.01 0.47 8.31 5.25 10.68 4.59 10.06 6.91 4.91 
47 1.58 1.92 4.78 0.20 0.17 0.48 0.03 0.61 0.24 0.96 
48 29.43 8.97 6.82 1.79 2.63 1.87 1.25 4.97 1.94 0.91 
50 66.30 6.25 3.64 1.11 1.73 0.86 0.79 2.39 1.73 0.61 
52 18.25 6.94 10.65 2.26 1.87 1.61 1.36 0.14 2.10 0.72 
53 42.40 7.30 4.03 2.08 2.55 1.25 1.91 2.90 2.11 0.73 
55 5.17 0.95 1.26 1.46 1.11 0.85 0.85 4.45 1.28 0.58 
57 1.57 0.52 0.79 1.17 0.51 0.81 0.44 1.11 0.06 0.84 
59 7.30 1.79 1.34 2.09 1.12 1.32 1.11 0.33 1.30 1.56 
60 1.29 2.35 2.66 0.90 1.19 0.45 1.26 2.28 0.92 1.15 
62 0.90 0.94 0.45 0.73 0.66 0.63 0.29 1.47 0.24 0.85 
66 15.89 11.65 6.08 1.52 1.68 1.99 1.45 0.54 1.65 1.94 
67 14.60 7.20 5.58 1.84 1.81 2.57 1.41 69.74 0.80 3.04 
68 15.13 3.77 9.79 25.07 1.74 7.31 21.38 4.73 4.72 8.85 
69 5.63 9.32 5.88 3.77 2.39 5.08 2.72 1.68 0.97 7.50 
Continue on Page 65 
  65 
Relative Gene Expression 
Patient 
PLK1 FOXM1 PTTG1 USP21 RCN2 DUSP12 USP1 S100P USP5 XBP1 
72 3.17 1.69 1.91 1.17 1.26 1.42 1.00 1.13 1.17 1.12 
78 27.10 15.23 9.23 2.40 6.43 3.10 1.72 2.43 2.93 1.04 
79 1.14 6.79 2.34 3.34 3.50 6.03 4.13 9.43 0.73 4.53 
83 17.68 12.77 7.51 4.09 4.55 3.38 2.83 3.57 0.89 11.33 
84 0.87 1.90 1.61 1.12 0.90 1.05 0.91 0.10 0.64 1.26 
87 2.62 3.75 2.01 2.28 0.92 1.38 1.38 2.48 3.89 0.70 
91 15.82 22.61 18.13 3.35 9.36 6.55 2.81 25.05 9.60 5.42 
92 3.01 2.60 2.05 2.43 1.41 1.60 1.82 1.45 2.13 1.42 
96 72.25 42.49 43.26 12.80 7.49 11.95 11.13 4.65 7.91 9.25 
99 37.22 9.22 4.82 2.49 2.19 3.37 2.37 0.51 1.44 1.83 
103 7.86 1.90 0.59 0.75 1.27 0.59 0.41 0.59 0.83 0.11 
104 28.72 5.49 2.54 1.44 1.40 1.16 1.25 0.47 1.05 0.92 
111 81.35 48.87 131.96 3.32 6.58 2.43 3.92 2.54 3.27 0.93 
116 5.68 1.67 4.28 0.61 1.12 0.68 0.87 1.77 0.34 0.57 
118 3.02 1.61 1.37 1.11 0.70 0.44 0.86 0.50 0.84 0.64 
120 11.19 3.00 4.95 0.87 1.10 0.80 1.39 0.92 0.79 1.23 
121 15.49 2.04 1.90 1.08 0.82 0.78 0.78 0.54 0.84 0.64 
126 3.74 1.96 1.67 2.38 1.16 1.50 1.60 3.69 4.22 1.20 
127 7.28 4.54 5.16 0.98 1.35 0.86 1.36 2.08 1.49 0.97 
131 41.56 15.65 2.29 1.99 3.53 1.74 1.08 2.56 2.27 0.81 
136 15.74 4.86 9.00 1.70 1.46 1.49 1.33 3.62 1.56 0.98 
137 2.12 3.18 3.26 1.55 1.89 1.36 0.91 2.07 1.39 1.31 
146 7.39 5.11 3.32 1.19 1.85 1.38 1.40 8.16 0.88 0.79 
Continue on Page 66 
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Relative Gene Expression 
Patient 
PLK1 FOXM1 PTTG1 USP21 RCN2 DUSP12 USP1 S100P USP5 XBP1 
148 22.90 6.22 5.20 2.52 1.77 1.82 1.82 1.34 0.78 1.15 
149 1.02 2.65 4.36 1.26 1.28 0.62 1.03 1.11 0.66 0.87 
150 12.59 10.39 4.66 6.26 2.43 3.83 1.88 4.51 2.20 3.83 
151 12.90 10.37 5.12 1.93 1.71 1.68 1.32 0.74 4.24 2.61 
153 12.00 5.24 19.79 2.61 7.03 13.41 3.01 0.88 2.33 9.67 
155 0.52 0.36 0.33 0.30 0.42 0.16 0.26 0.36 0.47 0.11 
164 6.68 2.75 3.97 1.30 1.37 0.95 0.79 0.93 1.76 1.64 
165 50.98 27.36 1.23 2.53 1.21 1.74 0.91 0.11 2.77 0.54 
170 57.44 11.08 6.83 2.73 1.51 1.65 0.64 1.70 1.32 1.59 
176 19.66 10.05 10.11 3.47 2.81 3.11 1.57 0.26 1.63 3.82 
177 33.43 12.02 1.70 0.79 0.73 0.98 0.84 0.62 1.19 0.55 
178 18.48 6.46 1.15 2.05 1.03 1.03 0.57 14.93 0.10 0.87 
183 20.82 6.51 7.24 2.20 1.00 1.67 0.97 2.23 0.55 1.51 
184 23.64 12.49 4.16 3.73 2.12 3.05 2.87 8.93 1.35 1.25 
 
Gene expression in every HCC tissues was quantified relative to the corresponding non-tumor tissues using 2-∆∆Ct method by real-time RT-PCR. 
PLK1: Polo-like Kinase 1 
FOXM1: Forkhead Box M1 
PTTG1: Pituitary Tumor-transforming Gene 1 
USP21: Ubiquitin Specific Peptidase 21 
RCN2: Reticulocalbin 2 
DUSP12: Dual Specificity Phosphotase 12 
USP1: Ubiquitin Specific Peptidase 1 
S100P: S100 Calcium Binding Protein P 
USP5: Ubiquitin Specific Peptidase 5 (Isopeptidase T) 
XBP1: X-box Binding Protein 1 
 
